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Abstract
Herpes simplex virus (HSV) entry requires four essential glycoproteins (gD, gH/gL, and gB) to enable
fusion between the virion envelope and the cellular membrane. The fusion cascade is activated by gD
binding to one of its receptors, nectin-1 or HVEM. Glycoprotein B (gB), a class III viral fusion protein,
mediates the fusion reaction, while data indicates that gH/gL acts as a regulator of gB. gB is trimeric and
has a 773 amino acid ectodomain with a highly hydrophobic membrane proximal region (MPR) (residues
731-773) and two fusion loops (FL) per protomer. The post-fusion structure of gB was solved from the
gB(730t) construct, which is truncated to remove the hydrophobic MPR residues. In this dissertation I
investigated the MPRs influence on gBs ability to interact with membranes. I hypothesize that the MPR
regulates fusion loop exposure by interacting with the fusion loops and masks them until fusion begins.
To investigate this process I constructed a series of MPR deletion, truncation, and point mutations using
both full-length mammalian expression vectors and purified baculovirus expressed protein. I found that
deletions in the MPR from full-length gB resulted in a disruption in cell surface expression in transfected
cells. This suggests the MPR is necessary for proper folding or transport of gB. Soluble gB MPR
truncations [gB(759t), gB(749t), gB(739t)] were expressed and purified using the baculovirus expression
system, and compared to MPR-less gB(730t) and full MPR containing gB(773t). I found that gB containing
an MPR segment were all compromised in their ability to bind liposomes in comparison to gB(730t),
which lacks any MPR residues. Supporting our hypothesis we found that residues 731 to 739 were
sufficient prevent liposome association and mutation of two aromatic residues, F732 and F739, to alanine
in gB(739t) restored gBs ability to bind liposomes. Together, my data suggests the MPR does indeed
regulate gBs ability to associate with liposomes, and that aromatic residues in the MPR are important for
this function. This supports our model that the MPR masks the gB FLs to prevent premature membrane
association and adds another layer of regulation to the HSV entry cascade.
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ABSTRACT

DEFINING A REGULATORY ROLE FOR THE HSV GLYCOPROTEIN B
MEMBRANE PROXIMAL REGION IN MEMBRANE ASSOCIATION
Spencer S. Shelly
Roselyn J. Eisenberg
Gary H. Cohen

Herpes simplex virus (HSV) entry requires four essential glycoproteins (gD, gH/gL, and
gB) to enable fusion between the virion envelope and the cellular membrane. The fusion
cascade is activated by gD binding to one of its receptors, nectin-1 or HVEM.
Glycoprotein B (gB), a class III viral fusion protein, mediates the fusion reaction, while
data indicates that gH/gL acts as a regulator of gB. gB is trimeric and has a 773 amino
acid ectodomain with a highly hydrophobic membrane proximal region (MPR) (residues
731-773) and two fusion loops (FL) per protomer. The post-fusion structure of gB was
solved from the gB(730t) construct, which is truncated to remove the hydrophobic MPR
residues. In this dissertation I investigated the MPRs influence on gBs ability to interact
with membranes. I hypothesize that the MPR regulates fusion loop exposure by
interacting with the fusion loops and masks them until fusion begins. To investigate this
process I constructed a series of MPR deletion, truncation, and point mutations using
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both full-length mammalian expression vectors and purified baculovirus expressed
protein. I found that deletions in the MPR from full-length gB resulted in a disruption in
cell surface expression in transfected cells. This suggests the MPR is necessary for
proper folding or transport of gB. Soluble gB MPR truncations [gB(759t), gB(749t),
gB(739t)] were expressed and purified using the baculovirus expression system, and
compared to MPR-less gB(730t) and full MPR containing gB(773t). I found that gB
containing an MPR segment were all compromised in their ability to bind liposomes in
comparison to gB(730t), which lacks any MPR residues. Supporting our hypothesis we
found that residues 731 to 739 were sufficient prevent liposome association and mutation
of two aromatic residues, F732 and F739, to alanine in gB(739t) restored gBs ability to
bind liposomes. Together, my data suggests the MPR does indeed regulate gBs ability to
associate with liposomes, and that aromatic residues in the MPR are important for this
function. This supports our model that the MPR masks the gB FLs to prevent premature
membrane association and adds another layer of regulation to the HSV entry cascade.
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CHAPTER 1
GENERAL INTRODUCTION
Herpesvirus overview
The viral family Herpesviridae consists of over 200 members infecting nearly
every species of animal (39). Herpesviridae family members are traditionally classified
on the basis of virion architecture. They contain an electron-opaque core of doublestranded DNA surrounded by an icosadeltahedral capsid. The capsid is surrounded by a
proteinaceous tegument and is surrounded by an envelope spiked with glycoproteins
(Figure I-1) (39, 143). There are eight known human herpesviruses (Table I-1), which
along with all herpesviruses are further divided into three subfamilies, alphaherpesvirus,
betaherpesvirus, and gammaherpesvirus. These subdivisions are based on genome
organization, biological properties, and cellular tropism. Alpha-herpesviruses have a
broad host range, wide cellular tropism, a short replication cycle, destroy infected cells,
and infect sensory ganglia where latency is often established. The human
alphaherpesviruses include varicella zoster virus (VZV) and Herpes simplex virus type 1
and type 2 (HSV-1 and HSV-2) (39). The betaherpesviruses have long replication cycles
and infect secretory glands and lymphoreticular cells. Betaherpesvirus infected cells
become enlarged and are known as cytomegalia, and the human viruses include human
cytomegalovirus (HCMV), human herpes virus-6 (HHV-6), and human herpes virus-7
(HHV-7) (39). T-lymphocytes or B-lymphocytes are the usual target cells of the
gammaherpesviruses, which have the most restricted host range of the three herpesvirus
subfamilies. The gammaherpesviruses infecting humans include Epstein Barr virus
(EBV) and Kaposi’s sarcoma associated herpesvirus (KSHV) (39).
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Figure I-1. Structure of HSV-1 virion. The icosahedral capsid (cyan) contains the
dsDNA genome, and is surrounded by the tegument layer (orange, portions removed).
The tegument is surrounded by the host-derived lipid bilayer (blue), which is studded
with the viral glycoproteins (yellow). Adapted from Grunewald et al (48).
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Abbrev.
HSV-1
HSV-2
VZV
EBV
CMV
HHV-6
HHV-7
KSV

Vernacular name
Herpes simplex virus 1
Herpes simplex virus 1
Varicella-zoster virus
Epstein-Barr virus
Cytomegalovirus
Human herpesvirus 6
Human herpesvirus 7
Kaposi’s sarcomaassociated herpesvirus

Designation
HHV-1
HHV-2
HHV-3
HHV-4
HHV-5
HHV-6
HHV-7

Subfamily
α
α
α
γ
β
β
β

HHV-8

γ

Table I-1. Human herpesvirus classification. The eight human herpesvirus are listed
above with their vernacular name, official designation, and herpesvirus subfamily
classification. Adapted from Fields Virology (39).
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HSV-1 and HSV-2 are prevalent in the United States with seroprevalence of 58%
and 17% of the adult population respectively (148). HSV-1 is the oral form of the virus
and typically causes lesions of the oral mucosa. The genital form, HSV-2, causes lesions
of the genital tissues. Closer analysis of HSV-2 seroprevalence in the U.S. reveals
women are infected at twice the rate of men, 23.1% versus 10.9% (148). In those
infected HSV establishes a latent infection in sensory ganglia that persists for the lifetime
of the host (39). HSV symptoms are rarely life threatening but cause varying degrees of
morbidity. Active HSV infection in immunocompetent adults can range from being
asymptomatic to the formation of oral or genital mucosal lesions (131). HSV can cause
corneal infections resulting in keratitis and rarely blindness or fatal encephalitis in
healthy individuals. Infection of neonates and the immunocompromised can result in
disseminated HSV that is life threatening (131). Approximately 1500 cases of neonatal
disseminated HSV are diagnosed each year in the United States (28) with a mortality rate
of 47% (144).

Virion structure
Four compartments make up the HSV virion, which are the genome, capsid,
tegument, and envelope with glycoproteins (Figure I-1) (48, 140). HSV is a large,
enveloped virus with a diameter of 125-200 nm and contains an approximately 150
kilobase pair linear double-stranded DNA with a G + C content of nearly 68% (39). The
genome contains two covalently linked segments, called the long (L) and short (S) unique
segments, which are linked by inverted repeats. The repeats allow rearrangement of the
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unique sequences yielding four possible genome arrangements (53). The HSV genome
encodes at least 70 polypeptides (39).
The HSV genome is enclosed by an icosahedral capsid made from four major
components (VP5, VP19C, VP23, VP26) and has been resolved by electron microscopy
in detail (152). VP5 is the major capsid protein, which oligomerizes to form ring-shaped
capsomers, while one VP19C and two VP23 molecules form timers. VP26 is located at
tips of the capsomers (39).
The capsid is surrounded by the closely associated tegument layer, which is made
of at least 22 proteins (140). Tegument proteins have multiple roles immediately upon
virus entry. These functions include virion host shut-off (vhs) by UL41 to halt host
protein synthesis (85). VP16 is an essential viral transcription factor and US11 prevents
the shutdown of protein synthesis by protein kinase R (PKR) (2, 106).
A lipid bilayer surrounds the genome, capsid, and tegument known as the viral
envelope. The envelope is derived from host lipid membrane and contains eleven
glycoproteins (gB, gC, gD, gE, gG, gH, gI, gJ, gL, gM, gN) and at least three nonglycosylated proteins (39). While five of these glycoproteins (gD, gB, gH, gL, gC) are
involved in entry four (gD, gB, gH, gL) are necessary and sufficient for the fusion with
susceptible cell membranes (55, 105). Glycoprotein C has dual functions including a
dispensable role in viral attachment and in immune evasion blocking the complement
pathway (57, 59, 83).

HSV replication cycle
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HSV transmission occurs through epithelial mucosa of the human host, usually by
direct contact between infected and uninfected tissues. The steps of infection include
viral attachment to the cell surface followed by fusion of the viral and cellular
membranes allowing viral entry (122). Viral replication occurs at the site of entry
leading to cell death and viral spread to innervating axons of the peripheral nervous
system. Retrograde transport along microtubules carriers the viral capsid with tegument
proteins to the neurons cell body and nucleus (32). Several tegument proteins, VP16 and
US11, are important to shutdown host synthesis and viral protein production as discussed
above.
Lytic infection of sensory neurons leads to destruction of the neuron, but often a
latent infection is established where the virus persists without neuronal destruction. In
the sensory neurons life-long latent infection is established in the trigeminal or superior
cervical ganglion for HSV-1 and the sacral ganglia for HSV-2 (93). During latent
infection the virus is protected from the host immune response in the immune privileged
neuronal site and the low level of HSV transcription. The latent HSV genome exists as a
circularized extrachromosomal episome in the neuronal nucleus, and only one viral
transcript called the latency associated transcript (LAT) is detectable in the cell (15). In
an incompetently understood process the latent virus can response to stimuli like stress or
UV light and reactivate to produce infectious particles. Reactivation leads to viral capsid
formation and anterograde transport down the axon to the axonal termini where virions
are assembled (93, 135). Ultimately a secondary lytic infection of the epithelial mucosa
occurs near the area of the previous primary infection with lesion formation or
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asymptomatic viral shedding (91, 93). To complete this complex replication cycle HSV
infects multiple cell types, and this correlates with the wide cellular tropism exhibited by
the virus in tissue culture.
HSV has the ability to infect epithelial, endothelial, fibroblasts, and neurons in its
human host (39). HSV also non-productively infects monocytes and T cells (107). In
vitro HSV infects most cell types tested, which is likely due to its ability to use multiple
cellular receptors.
As described above, attachment is mediated by envelope glycoproteins, and four
glycoproteins (gD, gB, gH, gL) are necessary and sufficient for attachment and fusion
with susceptible cell membranes (55, 105). The details of viral entry and membrane
fusion process will be discussed below. HSV fuses either at the cell membrane or
undergoes endocytosis and fuses with an endocytic vesicle releasing the viral capsid into
the cytoplasm. The capsid binds to the retrograde molecular motor dynein and is
transported along microtubules to the nuclear pore (32, 33, 35). Viral DNA is then
released into the nucleus were it circularizes forming an extra-chromosomal episome.
Expression of HSV genes products is highly regulated cascade using the cellular
RNA polymerase II (109). Three groups of genes have been defined based on the timing
of there expression: immediate-early (IE), early (E), and late (L) (39). Generally, the
immediate-early genes serve regulatory functions, the early genes participate in
translation and DNA replication, and late genes are structural proteins. Activation of IE
gene transcription requires the presence of tegument proteins (VP16) and cellular factors
(Oct1) prior to viral protein synthesis (126). Six IE proteins (ICP0, ICP4, ICP22, ICP27,
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ICP47, US1.5) are transcribed and translated two to four hours post infection (hpi) and
several are involved in the induction of E gene expression (39). Early gene transcription
reaches its peak 4-8 hpi, and several E proteins replicate cellular function such as
thymidine kinase (ICP36) and ribonucleotide reductase (ICP6). DNA polymerase
(UL30), DNA binding proteins (UL42, UL29), ORI binding protein (UL9), and
helicase/primase complex (UL5, UL8, UL52 are the seven E proteins necessary and
sufficient to carry out viral DNA replication (16). The onset DNA replication leads to a
reduction in E expression and the increase in expression of L genes encoding structural
elements of the virion including glycoproteins.
HSV DNA replication initiates after the linear viral genome is delivered to the
nucleus and circularized. DNA replication is thought to originate by a bidirectional theta
mechanism, which is followed by rolling-circle replication resulting in head-to-tail
concatemers of HSV genomes (16). DNA concatemers are cleaved into individual
genome segments during packaging into the preformed viral capsids. The resulting
nucleocapsid are enveloped by bud through the inner nuclear membrane (141), but
competing theories for the HSV egress route have been presented.
Historically, the double envelopment model has been the most widely accepted
model. In this model capsid particle are enveloped by the inner nuclear membrane
envelope, fuse with the outer nuclear membrane, and are released to the cytoplasm. The
capsids then association with tegument proteins and are re-enveloped by a cytoplasmic
organelle, likely budding into the Trans Golgi Network for maturation and transported
through the vesicular secretory pathway (23, 90). A second model provides two
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pathways for egress. First, a minority of capsids are enveloped by the inner nuclear
membrane and travel intraluminally through the Rough ER (RER) to Golgi cisternae and
package in to transport vesicles. A second, primary route allows capsids direct passage
from the nucleus to the cytoplasm through enlarged nuclear pores. In the cytoplasm they
can bud into cytoplasmic membranes (23, 78). Whatever the mode of envelopment the
end result is infectious HSV particles surrounded in a glycoprotein studded envelope.

Viral entry strategies
Viral entry pathways are determined by interactions at the cell surface, and these
critical interactions regulate the process viral genetic material uses to cross the cellular
lipid bilayer. Both non-enveloped and enveloped viruses must accomplish this task. The
non-enveloped viruses, lacking a lipid bilayer of their own, must transfer their genome
across the cellular bilayer. Enveloped viral genomes must transit both the viral and
cellular bilayers (51). The strategy used by each virus is dictated by the particular
cellular conditions encountered at the site of penetration (137)
Non-enveloped viruses, lacking a lipid bilayer, use three main strategies to get
their genetic material across the cellular membrane. These strategies include transient
lipid rearrangement, pore formation, and gross membrane disruption (98). Nonenveloped viral particles often require additional maturation steps, such as proteolysis
and conformational alteration to be primed for cellular invasion. At the target cell each
virus type is primed by a specific set of signals including receptor binding, low pH,
protease cleavage, chaperone-assisted morphological changes, or divalent cation
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chelation. These triggers regulate capsid rearrangements known broadly as uncoating
and help ensure the virus is in the proper state and location when activated for entry.
Poliovirus, a member of the family Picornaviridae binds its cellular receptor CD155 and
undergoes a conformational change exposing an amphipathic α-helix in the capsid
protein (54, 89). The α-helix is important for membrane penetration, pore formation, and
ultimately genome release into the cytoplasm (98, 139). Membrane pore formation, as
described above for Picornaviridae, is also employed by the Parvoviridae and Reoviridae
families, to facilitate genome release into the cytoplasm (1, 38, 62, 139). Other nonenveloped viruses such as adenovirus cause gross membrane disruption by lytic factor
release facilitating genome entry into the cell (84).
Enveloped viruses depend on a mechanism capable of facilitating fusion between
the viral and cellular membranes for their genetic material to gain entry. Fusion between
two bilayer membranes is a thermodynamically favorable process with a high kinetic
barrier of 40-50 kcal/mol (71). In enveloped viruses fusion proteins provide this
mechanism and catalyze membrane fusion by overcoming the kinetic barrier using the
free energy of conformational change. The described viral fusion proteins contain
several common characteristics. They are type I membrane proteins with a large
ectodomain and two membrane-interacting regions, the C-terminal transmembrane
anchor and a hydrophobic patch or fusion peptide. Also, they have a cytoplasmic tail and
are trimeric in their post-fusion state (51, 145). Viral fusion proteins are membrane
bound with large ectodomains folded into a metastable pre-fusion state (51). To
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overcome the high energy barrier of membrane fusion a fusion protein undergoes
conformational change and uses the energy released to drive fusion.

Viral Fusion Proteins
Three classes of viral fusion proteins, class I, class II and class III, are recognized
based on their structure and mechanism of fusion, and are exemplified by influenza
hemagglutinin (HA), tick-borne encephalitis virus (TBEV) E protein, and vesicular
stomatitis virus (VSV) glycoprotein G respectively (Figure I-2) (95, 96, 111, 113, 120).
Across these three classes of viral fusion proteins the route for catalyzing viral-cell fusion
is believed to follow a similar process using the free energy liberated by conformational
change to bring the viral and cellular membranes together (Figure I-3) (51). Fusion
proteins while diverse in sequence and structure all catalyze fusion using the same
general process resulting a trimeric active state and post fusion structure. Unique
regulatory steps are present in each class, and even for each particular virus, providing
control mechanisms for the fusion process (145).
The surfaces of mature enveloped viral particles are covered in fusion proteins in a
metastable fusion-competent state (Figure I-3A). A triggering event, specific to each
fusion protein, leads to conversion into to a prehairpin intermediate homotrimer. The
prehairpin intermediate (Figure I-3B) forms a bridge between the viral membrane and
target membranes connected though the C-terminal transmembrane anchor and the
hydrophobic fusion peptide, respectively. Next a series of conformational changes, or
fold-back steps occur bring the two membrane inserted elements, the fusion peptide and
11	
  
	
  
	
  
	
  

transmembrane anchor, together to create a trimer-of-hairpins (Figure I-3C-D) (25, 88).
Through the fold-back process the membrane becomes distorted, progressing through
hemifusion, small fusion pore formation, and finally the establishment of a stable large
fusion pore (Figure I-3D) (51, 145). Ultimately, formation of a stable six-helix bundle
results in the fusion of the viral and cellular membranes and allows the transfer of the
viral nucleocapsid into the cytoplasm to initiate replication (Figure I-3E).

Class I Fusion Proteins
Class I fusion proteins are trimeric pre-fusion and post-fusion with a characteristic
long central α-helical coiled-coil, two heptad repeat regions, and N-terminal fusion
peptide, which is initially concealed at the primer interface (51, 145). Typically, the class
I fusion protein is translated as a single polypeptide and cleaved into 2 proteins during
post-translational processing or upon exposure to low pH in the endosome. The fusion
active portion contains the membrane anchor and remains attached to the viral
membrane, while the second portion contains the receptor binding motif (145).
Fusion between the viral and cellular membranes occurs generally as outlined
above. Briefly, the fusion protein is attached to the viral membrane by the
transmembrane domain and to the cellular membrane by insertion of the fusion peptide.
Conformational changes, initiated by a trigger (receptor binding or low pH), drive the
fusion protein into a hairpin intermediate-state. Then self-association of the heptad
repeat regions support the formation of a stable six-helix bundle (6HB) in the
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Pre-fusion

Post-fusion

A
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B
	
  

C

	
  

Figure I-2. Class I, II, III fusion proteins; pre-fusion and post-fusion structures. (A)
Class I fusion protein Influenza virus HA2 crystal structures is shown. (B) Class II
fusion protein TBEV E protein crystal structures. (C) Class III fusion protein VSV G
protein crystal structures. (A-C) The pre-fusion states are on the left and post-fusion
states on the right. Functional domains are identified by color. Adapted from White et al
(145).
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Figure I-3. Model of membrane fusion. (A-E) The proposed sequence of events of
membrane fusion mediated by viral fusion proteins. Class I, II, III fusion proteins are
thought to all follow this similar general series of steps to promote membrane fusion.
Adapted from Harrison et al (51).
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trimeric post-fusion form resulting in membrane fusion (145).
Viruses containing class I fusion proteins include paramyxoviruses, retrovirues,
filovirues, coronaviruses, and orthomyxoviruses (17, 42, 75, 100). Influenza, a member
of the Orthomyxoviridae family, contains the prototypical class I fusion protein, HA,
which serves a model for the class. A 220 kDa homotrimer with both receptor binding
and fusion activity, HA's pre-fusion form was the first crystallized fusion protein, and HA
remains one of the best studied viral fusion proteins (Figure I-2A) (145, 146). HA
consists of two disulfide-linked subunits, HA1 and HA2, derived by proteolytic cleavage
of the HA0 precursor. Cleavage of HA0 occurs in the trans-golgi network (TGN) and
HA1 contains the receptor binding domain, while HA2 forms the central α-helical coiledcoil region and contains the fusion active region with the heptad regions (HR1 and HR2)
and the fusion peptide (51, 120). The placement of the receptor binding domain and the
fusion functional domain on separate proteins is typical of class I fusion proteins.
Binding to the host ligand, sialic acid, through the HA1 subunit leads to
endocytosis of the influenza virion (120). Exposure to low pH following endocytosis
induces irreversible conformational change in HA and release of the fusion peptide from
its protected position allowing insertion into the target membrane. The pre-hairpin
intermediate form the fusion peptide is inserted into the target membrane and the
transmembrane domain anchors HA to the viral envelope. Now fusion protein spans the
distance between the viral and target membranes (18, 145). Next, HA2 folds back as the
HR regions come together drawing the transmembrane domain and fusion peptide
together with their associated viral and cellular membranes, respectively. In the final
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post-fusion form HA has folded back on itself to form a trimer of hairpins with a long
central trimeric alpha-helical core packed at the C-terminal region by three shorter
helices, also referred to as the 6 helix bundle (6HB) (Figure I-2A) (27). Through
conformation change this class I fusion protein has moved from a high energy metastable
prefusion state to a more stable lower energy postfusion state and used the energy
released to drive membrane fusion (51, 145).

Class II Fusion Proteins
The viral glycoproteins E1 of Semliki forest virus (SFV) and E protein of Tickborne encephalitis virus (TBEV) are class II fusion proteins from Alphavirus and
Flavivirus genera, respectively (Figure I-2B). These are small, enveloped, positive-sense
RNAviruses with a nucleocapsid and a lipid bilayer containing the viral transmembrane
(TM) proteins. SFV E1 and TBEV E protein class II glycoproteins have distinct primary
sequences with little homology, but they have significant secondary and tertiary structural
homology (67). Class II fusion proteins are thought to use a by a similar fold-back
process as class I fusion proteins to bring the membranes together and facilitate fusion
(145).
Several key factors distinguish SFV E1 protein and TBEV E protein from class II
fusion proteins from class I fusion proteins informing the class separation (77). Class II
fusion proteins are primarily composed of β-sheets with little α-helical content, have
internal fusion loops at the tip of β-strands, are anti-parallel dimers lying flat on the
virion surface in their pre-fusion form, and require a regulatory protein for proper folding
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(67, 145). Class II proteins associate with a regulatory protein during post-translational
processing. The regulatory protein may function to maintain the protein in its native
metastable (67). Cotranslation with a regulatory protein in class II fusion proteins
differentiates them from class I fusion proteins that do not associate with a regulatory
protein in this way.
SFV fusion protein E1 is cotranslationally expressed with regulatory protein p62.
After insertion into the endoplasmic reticulum the p62-E1 complex folds and continues
transport along the secretory pathway toward the plasma membrane (67). Late in the
secretory pathway the p62 is cleaved by the cellular protease furin. Furin cleavage of p62
is a critical regulator step and produces an E2 transmembrane protein that remains stably
associated with the p62/E1 dimer (68). E2 contains the receptor binding domain and
shields the internal fusion loops on E1 from premature exposure. Each SFV virion buds
from the plasma membrane covered with 80 trimers of E2/E1 heterodimers laying flat on
the surface with T=4 icosahedral symmetry (46, 68, 114, 145).
SFV and TBEV both undergo receptor-mediated endocytosis and require a low
pH to trigger fusion. As the pH decreases SFV E2/E1 dimer undergoes a conformational
change allowing exposure of the E1fusion loop and its insert into the target
membrane(67). This conformational change also results reorganization of E1 into
trimmers, which are necessary for hairpin formation and fold-back leading to membrane
fusion and a trimeric post-fusion structure.

Class III Fusion Proteins
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Class III fusion proteins were initially characterized through the surprising
structural homology between vesicular stomatitis virus (VSV) glycoprotein G and HSV-1
glycoprotein B, which contain no sequence homology and are a negative-stranded RNA
virus and a DNA virus, respectively (56, 111). VSV is a member of the Rhabdoviridae
family, while HSV represents the large Herpesviridae family (39). The VSV G structure
has been resolved at neutral and low pH providing a picture of the pre-fusion and postfusion structures (Figure I-2C) (111, 113). Analysis of these structures revealed
characteristics found in both class I and class II fusion proteins, but an overall structural
organization that was different than any previously described fusion protein (110). The
resolved structures showed that VSV G fusion proteins are trimeric pre-fusion and postfusion like a class I fusion protein and contain central α-helical structural elements.
Class III fusion proteins also contain β-sheets and have internal fusion loops, both
important secondary structural motifs of class II fusion proteins (111). Importantly, class
III fusion proteins appear to use conformational changes to power the formation of a
hairpin structure that pull the viral and target membranes together in a similar manner as
both class I and II fusion proteins indicating a common overall framework for achieving
membrane fusion.
Comparison of HSV-1 gB structure and VSV G post-fusion structure reveals
similar folds and, likely, a common evolutionary origin not evident in primary sequence
comparison (56, 111, 127). Other class III fusion proteins identified based on structural
homology to VSV G include Epstein-Barr virus (EBV) gB and baculovirus gp64 (9, 66).
In comparison to VSV G where both pre-fusion and post-fusion structures have been
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resolved, the gBs and gp64 are presumed to be post-fusion conformations. They are
homotrimeric with a long central coiled-coil like class I, and internal bipartite fusion
loops similar to the single fusion loop in a class II fusion protein (117).
VSV is a small, negative sense, enveloped RNA virus with a bullet shaped
morphology resembling other Rhabdoviruses, such as rabies virus (39). VSV has been
widely used as a model system due to its broad cell tropism, one of the broadest of any
enveloped virus, and the ability to grow large quantities of virus at high titers (39, 74).
Many aspects of this bullet shaped rhabdovirus, from entry and fusion to replication and
assembly, are well characterized (39). VSV is a virus of economic concern for the
livestock industry causing significant morbidity, but its extensive study is largely due to
its tractability in experimental systems.
The VSV receptor remains unidentified, but may aspects of its entry have been
well-characterized biochemically and through structural analysis. The VSV envelope is
covered with a single protein, the 495 amino acid, type I transmembrane protein spikes
know as glycoprotein (G), which functions in both attachment and entry (30). Following
receptor binding VSV is taken into endocytic pathway of target cells by clathrin-mediated
endocytosis (65). Exposure to acidic pH of the endsome induces significant
conformational changes in VSV G resulting in fusion and ultimately nucleocapsid release
(111, 113).
Earlier biochemical analysis identified three conformational states in G;
prefusion, activated hydrophobic, and post-fusion (44, 110). The post-fusion state was
recognized as antigenically distinct from the first two, and a shift toward the post-fusion
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state observed upon exposure to low pH. Interestingly, these antigenic changes observed
in G at low pH were reversible upon return to neutral pH, a property not observed in class
I and class II fusion proteins (43, 112).
As described above, the pre-fusion and post-fusion VSV G ectodomain structures
have been resolved (Figure I-2C), and were identified along with HSV-1 gB to represent
a new class of fusion proteins, class III (56, 111, 113). To mediate viral entry into cells
VSV G and baculovirus gp64 are sufficient, and serve the attachment, receptor binding,
and fusion functions without the need for other viral proteins (14, 110, 150). HSV gB is
not sufficient to mediate fusion on its own even through its structure resembles postfusion VSV G. HSV requires three other proteins, gD and gH/gL heterodimer, along
with gB for successful entry and fusion. (105).

Herpesvirus entry
Herpesviruses encompass a large family of enveloped viruses with a conserved
fusion mechanism. Nine human herpesviruses have been characterized, and in excess of
130 herpesviruses have been identified in all species (39). They are dispersed across the
three subfamilies; alpha-, beta-, and gammaherpesviruses. The alphaviruses are HSV
types 1 and type 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV). The
betaherpesviruses include cytomegalovirus (CMV) and human herpesviruses 6A, 6B, and
7 (HHV-6A, HHV-6B and HHV-7). The two gammaherpesviruses are Epstein-Barr
virus (EBV) and Kaposi’ sarcoma herpesvirus (KSHV) also known as human herpesvirus
8 (HHV-8) (55). Across all herpesvirses entry and fusion is mediated by homologs of
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three highly conserved proteins, gB and gH/gL (Figure I-4). In addition to these
conserved entry proteins a receptor binding protein is necessary, and a wide variety are
used throughout the Herpesviridae (Figure I-4). HSV and its entry requirements are
further evaluated below.
HSV entry has historically been reported to occur at the plasma membrane by
direct fusion as seen in Vero cells (Figure I-5A) (147). Entry through the endosomal
pathway has also been reported, under both neutral and acidic conditions (99).
Interestingly, the mode of entry varies by cell type, but in all cases gD and the core fusion
machinery gH/L and gB are necessary. Entry through the endocytic pathway seems to
predominate in HeLa, CHO-K1 expressing gD-receptor nectin-1, and primary human
keratinocytes, and requires acidification for successful fusion (Figure I-5B) (99). B78H1
mouse melanoma cells expressing gD receptor nectin-1 are reported to use the endocytic
pathway for entry but without a requirement for low pH as seen in the cell types above
(Figure I-5C) (92). HSV’s ability to infect a wide variety of cell types may be a function
of the multiple receptors it can bind to initiate successful entry, and this variety may
contribute to the varied entry pathways.
HSV employs four glycoproteins proteins in a complex entry mechanism, and
each is required for successful entry. These four proteins are gD, gH, gL, and gB (Figure
I-6). Glycoprotein D (gD) is the receptor binding protein for HSV and has three known
cellular receptors, which are herpes virus entry mediator (HVEM), nectin-1, and 3-OSmodified heparan sulfate moieties (121). The core herpes fusion machinery includes
gH/gL heterodimer and gB, which are highly conserved throughout all herpesviruses.
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Figure I-4. Entry proteins of human herpesviruses. All eight human herpesviruses
require gB and gH/L for entry. Recepter binding is performed by gD in the
alphaherpesviruses except for VZV, which uses gE. Betaherpeseviruses and
gammaherpesvirues bind receptor(s) using gB, gH/gL, or an accessory protein. Adapted
from Heldwein and Krummenacher (55).
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Figure I-5. Routes of HSV entry. (A) Entry into Vero cells occurs at the plasma
membrane and is pH-independent. (B) HSV enters CHO-nectin-1 expressing cells by
pH-dependent endocytosis, but cannot enter CHO cells without nectin-1. (C) Like CHO
cells, B78 cells require a transformation with a gD receptor. Here B78 cells are
transfected with nectin-1. Entry into these cells is by pH-independent endocytosis.
Adapted from Milne et al (92).
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Importantly, the four glycoproteins (gD, gH/gL, gB) and a receptor (HVEM or nectin-1)
are necessary and sufficient to complete cell fusion (4, 138).

gC
Glycoprotein C (gC) is a nonessential glycoprotein that plays a role to aid entry
by binding heparin sulfate proteoglycans (HSPG) fostering virus-cell attachment (55).
Initial viral attachment occurs through the non-essential glycoprotein gC and
independently through gB by binding heparan sulfate proteoglycans (HSPG) (12, 123).
Cells deficient in proteoglycan synthesis have a significant reduction in viral infection,
but remain permissive to HSV indicating HSPG is not essential for infection (10).
Additionally, gC mutant HSV virions remain infectious, albeit at a lower level, while gB
null virions are non-infectious (21, 57). These data support that gC and HSPG binding
are nonessential for HSV entry, while gB is essential. gB, the focus of this thesis, will be
discussed further in later sections.

gD
HSV-1 gD, the receptor binding protein, binds one of three cellular ligands, and
plays an important role in virus tropism. gD is a 369 amino acid type 1 membrane
protein with a immunoglobulin V-like fold at its core as seen by its crystal structure. Nand C- terminal extension wrap around the core, and gD is thought to form a homodimer
on the virion surface (Figure I-6). Understanding of gD binding to its main cellular
ligands, HVEM or nectin-1, has been significantly advanced by successful crystallization
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of gD in complex with each ligand (24, 31). Glycoprotein D binding with its receptors is
essential for viral entry, and data supports that this binding transmits a single downstream
that allows gH/gL and gB to complete fusion with the cell membrane. In vivo both gD
receptors, HVEM and nectin-1, seem to be relevant for continued infection. Patient
isolated virus samples retain the ability to use either receptor no matter the location of the
lesion from which virus was collected (70).
HVEM is a tumor necrosis factor-like receptor found in the greatest abundance on
T cells (Figure I-6). HVEM is widely expressed, but is found at high levels in the spleen,
thymus, lungs, B cells, monocytes, and T cells (72). For HSV entry HVEM is a
functional receptor in in activated T cells, oral epithelial cells, and corneal fibroblasts (61,
97, 134). HVEM has several natural ligands providing stimulatory signals (LIGHT,
lymphotoxin alpha) and inhibitory signals (BTLA and CD160) that together modulate the
immune response (47, 52, 87, 116). Interestingly, HSV does not replicate successfully in
T cells (128). This provides the intriguing possibility that gD-HVEM interactions may
modulate the host immune response, possibly aiding virus replication and latency.
Nectin-1, a cell adhesion molecule located at adhesion junctions, is found at sites
distinct from HVEM, and is abundant on epithelial cells, fibroblasts, and on neurons (94,
97, 130). Nectin-1 and its family members (nectin-2, -3, -4) contain three Ig-like
domains, a transmembrane domain, and cytoplasmic tail (Figure I-6). Nectin-1 acts as a
receptor for HSV-1 and HSV-2, and is the primary receptor on epithelial cells and
neurons (61, 119). Nectin-1 is also a receptor for pseudorabies virus (PRV) and bovine
herpesvirus type-1 (BHV-1), both alphaviruses like HSV (45).
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gH/gL
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viral envelope

Figure I-6. Proteins required for HSV entry. Four essential glycoproteins (gB, gD, and
gH/gL) are required for HSV entry. gD interacts with one of the key cellular receptors,
HVEM or nectin-1. The crystal structures of each glycoprotein and receptor are depicted.
Adapted from Eisenberg et al (36).
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The third gD receptor, heparan sulfate proteoglycans (HSPG) are carbohydrate
chains covalently linked to proteins. HSPGs are secreted into the extracellular matrix or
are cell associate. They are expressed ubiquitously on mammalian cells and interact with
growth factors, cytokines, chemokine, and morphogens. HSPGs have a wide variety of
important functions in development, morphogenesis, cell adhesion, and hemostasis (37).
HSPGs are made of a core protein and one or more linear polysaccharide, or
glycosaminoglycan (GAG), chain covalently attached in the ER. The HS undergo a
series of processing reactions in the Golgi to deacetylate, sulphonate, and otherwise
modify the chains for its specific role and location (13).
3-O-sulfated heparan sulfate (3-OS-HS) only functions as a receptor for HSV-1.
3-OS-HS binds gD in several cell lines (HeLa, Vero), and is an important receptor for
primary corneal fibroblast infection (118) (101, 133).

gH/gL
The gH/gL heterodimer is a part of the core herpesvirus fusion machinery and is
highly conserved. HSV-1 gH is a 838 amino acid with a large ectodomain and membrane
anchor, while gL is 224 amino acids protein without a transmembrane segment (26). The
heterodimer requires formation of the 1:1 gH/gL complex where gL functions as a
chaperone essential for proper processing and trafficking of gH (103). gH/gL is a major
target for HSV neutralizing antibodies supporting its importance in the entry process
(103). Several studies have suggested gH/gL may have fusogenic properties due to
identification of fusion activity of gH derived synthetic peptides and the predicted
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presence of heptad repeat regions in gH (40, 41). Recently, the gH/gL crystal structure
was solved for HSV-2 as well as EBV and a fragment of PRV gH, and had no structural
homology to a known fusion protein. Additionally, the predicted heptad repeat region
formed helices excluding a role in fusion (Chowndary 2010)(6, 86). An interaction
necessary for cell-cell fusion was identified between gH/gL and gB using bimolecular
complementation (4, 5). Additionally, gH/gL and gB cofloatation with liposomes was
observed at low pH (22). These data support the idea that interaction between gH/gL is
necessary for fusion.

HSV glycoprotein B
Glycoprotein B is the most highly conserved herpesvirus entry proteins protein.
gB is 904 amino acid protein produced from a 934 amino acid polypeptide with the 30
amino acid signal sequence cleaved during the maturation process (Figure I-7). gB
contains a 697 amino acid ectodomain, a 68 amino acid membrane proximal and
transmembrane domain, and a 109 amino acid cytoplasmic domain. The membrane
proximal and transmembrane region spans amino acids 731-794, and contains three
hydrophobic domains. Residues 731-773 contain the two hydrophobic domains and are
named the membrane proximal region (MPR). The third hydrophobic region represents
the transmembrane domain anchoring gB to the viral membrane (108).
gB is structurally homologous to VSV G and baculovirus gp64, but does not share
sequence homology with these fusion proteins (56, 66, 111). This structural homology
identified gB as a class III fusion protein. gB is trimeric with two fusion loops per
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protomer, β-sheets, PH domain, and a long central α-helices (56). gB was suspected to
have fusion activity before the structure was resolved due several pieces of data. In the
early studies of HSV a syncytial phenotype was observed, and the genotype was localized
to point and truncation mutants in gB (20, 132). Mutational analysis of the putative
fusion loop region through point mutants and linker insertions identified mutations that
altered gB’s ability to mediate cell-cell fusion (49, 50, 82). Point mutations in the
putative gB fusion loops (W174, Y179, H263, R264) decreased or completely abrogated
the ability of soluble gB (730t) to associate with liposomes (49). These data further
support a role for gB in fusion and entry.
Detailed analysis of the gB crystal structure identified five distinct structural
domains in the 85Åx80Åx160Å elongated trimer, which resembles the size and shape of
spikes observed on HSV-1 virions by electron microcopy (56, 125). The crystallized
construct contained HSV-1 residues 133 to 730, and was produced in a baculovirus
expression system as a soluble protein (Figure I-7). The soluble protein was then purified
by immunoaffinity chromatography and named gB730t. The resulting trimeric structure
contains three protomers, each with five domains. Domain I (residue 153 to 363) forms
the base and contains a PH-like domain and a β-sandwich made of 2 β-sheets. PH
domains facilitate phosphoinosital binding and protein-protein interactions, which may be
important for gB function (76). Importantly, the two proposed fusion loops occupy the
folds in two adjacent β-strands of each protomer and project toward the membrane (56).
The specific properties of gB fusion loops will be discussed in a later section.
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Figure I-7. Structure of HSV gB. (A) domain architecture of gB. Domains are
highlighted in different colors with their first residue position shown. (B) Ribbon
diagram of a single gB protomer with domains labeled and colored identically to (A). (C)
Surface representation of gB trimer with domains of one protomer colored according to
(A). Adapted from Heldwein et al (56).	
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Domain II is formed by two discontinuous segments and forms another PH-like
domain. Domain III is made of 3 discontinuous segments and contains a long α-helix
that with the adjacent protomers forms the central coiled-coil of gB with many essential
trimer contacts (56). Domain III bears a strong similarity to the central coil-coiled in
class I fusion proteins.
Domain IV, the crown, is also formed by two discontinuous segments that are
linked by a disulfide bond forming a globular structure at the top of the structure (56).
No structural relatives have been described for this region. Notably, several neutralizing
monoclonal antibodies have been mapped to similar surface epitopes suggesting domain
IV is exposed on the virion surface (56, 58).
Domain V is a long extension (residues 670 to 725) stretching from the top to the
bottom of gB. This long extension fits in the groove between the other two protomers,
but has no contact with any other portion of its own protomer. These interactions may
help stabilize the trimer. The crystallized structure ends at amino acid 725, leaving the
remaining C-terminal portion of the ectodomain, the transmembrane domain, and the
cytoplasmic domain unresolved. The missing ectodomain contains the hydrophobic
MPR (residues 731-773) that was removed from the soluble gB construct used for
crystallization due to its hydrophobic character (56). Chapter II will focus on
investigating what role the MPR plays in gB fusion.
The available evidence suggests that the HSV gB structure is the post-fusion form
due to similarities with the extended post-fusion VSV G. In the future examination of a
second, presumably pre-fusion gB structure would provide evidence that the current
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structure is the post-fusion form (111). Several studies report conformational changes in
gB when exposed to low pH (22, 34). Analysis of a low pH structure of gB detected a
major shift in the position of fusion loop 2, but no global pH-dependent changes in the
fusion protein were noted. This fusion loop 2 shift is hypothesized to be important for
endocytic entry of HSV, but the observed changes are not the global rearrangements one
would anticipate for the pre-fusion form (124). Antigenic changes detected in soluble gB
at low pH caused a change in the oligomeric structure toward the monomeric state. Upon
return to a neutral pH these changes were reversible (34). Reversibility from pre-fusion
to post-fusion is a key characteristic of VSV G and class III fusion proteins, and it
appears gB has a reversible component to its conformational changes due to pH.
Significantly, the conformational changes detected in gB antigenically and by crystal
structure do not appear as profound as those observed for VSV G (110, 111). Using
structural data to develop a model of the gB pre-fusion structure and its transition to postfusion provides detailed analysis of fusion protein. Until a pre-fusion structure is solved
a variety of techniques including targeted mutations, antigenic analysis, and lipid binding
assays are used to continue to dissect gB’s role in HSV entry and fusion.
Using the presumed post-fusion structure of gB, and the homologous VSV G
structural data, targeted mutagenesis was used to evaluate the proposed HSV fusion
loops. The two HSV gB fusion loops (FL), aa 173 to 179 and 258 to 265, in domain I
were mutated at structurally significant residues. Mutation of gB FL residues W174,
Y179, and A261 resulted in loss cell-cell of fusion, and mutations at W174, Y179, H263,
R264 led to impairment or loss of liposome association (49, 50). The availability of the
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crystal structure allowed characterization of regions important for viral fusion and
infection led to a functional map of the gB structure as described below.

gB Functional Regions
Mapping functional regions (FRs) using neutralizing antibodies is a common way
to identify important regions. Numerous studies have used monoclonal antibodies to
identify FRs of gB (3, 49, 50, 82, 104). Careful characterization of a 67 monoclonal
antibody panel to HSV gB identified eleven neutralizing antibodies and facilitated the
identification of functional regions. An overlapping peptide panel was used to identify
epitopes and then the epitopes were mapped onto the HSV-1 gB ectodomain structure
identifying four FRs (11). The four FRs are spread over the entire ectodomain with some
spanning multiple structural domains (Figure I-8).
FR1 includes the domains I and V, contains the putative fusion loops, and is
recognized by several neutralizing monoclonal antibodies. Monoclonal antibody SS55
was mapped to domain I, and is a potent neutralizer. Another FR1 virus neutralizing
antibody, SS144, mapped to the long α-helix of domain V near the carboxy-terminus of
the gB crystal structure (11). Interestingly, both SS55 and SS144 block soluble gB(730t)
from associating with liposomes in a coflotation assay (49). The presence of the putative
fusion loops, multiple neutralizing antibodies, and the disruption of liposome association
strongly suggests FR1 is important for virus entry and fusion.
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Figure I-8. gB functional regions. HSV gB FRs are defined by the epitopes
of neutralizing MAbs: SS55/SS106/SS144 (FR1, blue and red, fusion domain),
C226/H1838/H1781 (FR2, green, gH/gL interaction domain), SS10/SS67-69 (FR3,
orange, receptor-binding domain). The epitope of MAb H1817 (FR4, dotted circle) maps
to the unresolved N-terminus. (A) Ribbon diagram of gB protomer with functional
regions outlined in black. Representative monoclonal antibodies used to define these
regions are listed. (B) Space filling model of gB trimer with functional regions labeled.
The fusion loops are indicated at the bottom of the structure. Adapted from Hannah et al
and Eisenberg et al (36, 49).
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FR2 is on the outer surface of domain II, and represented by C226 neutralizing
antibody. C226 type-common recognizing both gB1 and gB2, and identifies domain II as
critical to HSV entry. FR3 encompasses residues located in domain III and domain IV
includes the epitope of neutralizing antibody SS10. The SS10 epitope includes residues
640-670, which are highly conserved among herpesviruses (56). This epitope is in
domain IV at the top or crown of the structure opposite the viral membrane in the
presumed post-fusion structure. Interestingly, SS10 blocks soluble gB’s ability to bind to
cells, but does not interfere with gB liposome association (11, 49). FR4 is formed by a
region of the gB N-terminus that was not solved in the crystal structure, and contains the
gB heparin sulfate binding region (11, 12).

Membrane Proximal Region
The membrane proximal region (MPR) is a portion of the ectodomain adjacent to
the transmembrane domain of viral fusion proteins. The MPRs of viral fusion proteins all
show an abundance of hydrophobic and aromatic residues (W, Y, F), and thus have high
hydrophobic character. In contrast, the number and spacing of these aromatic residues
vary with each fusion protein (7) (29). Mutations in the MPR of multiple fusion proteins
including HIV1 gp41 (115), HPIV 2 F protein (136), SV5 F protein (151), VSV
glycoprotein G (63, 64), baculovirus gp64 (79), and HSV gB (82) indicate they play
important roles in the regulation of membrane fusion. It is thought that the aromatic and
hydrophobic properties of MPRs indicate a function in bridging the gap at the lipid
interface between aqueous and hydrophobic environments (7, 69).
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The seventeen residue membrane proximal region of HIV-1 gp41 is known as the
membrane proximal external region (MPER), and is involved in virion assembly and
infection (115). The structure of this tryptophan rich region of gp41 was recently solved.
The MPER crystal structure places three aromatic side chains per monomer facing
towards the membrane on a non-classical coiled-coil structure (19). These aromatic
residues are positioned for membrane insertion and data supports the notion that gp41
MPER structural motif aids the generation of viral membrane curvature and ultimately
fusion (19). The deletion of seventeen residues of the MPER or mutation of five
conserved tryptophan residues to alanine abolished cell-cell fusion. Single tryptophan
mutations resulted in decreased infectivity (115). Interestingly, the epitope for a broadly
neutralizing antibody, 2F5, is located in the MPER highlighting the importance of this
structure in infection (60).
The twelve residue membrane-proximal region of the human parainfluenza virus
type 2 (HPIV2) F protein, is necessary for fusion activity but not surface expression
(136). Importantly, three residues (N475, F476, and F477) were identified to be critical
for cell fusion activity, and when singly mutated to alanine F protein was unable to
mediate hemifusion. The inability of the F protein MPR mutants to initiate hemifusion
indicates the MPR is involved in lipid mixing (136).
The SFV class II fusion protein E1 has a MPR that is thought to play a role in the
conformational change during fusion. Although structural data is unavailable, sitedirected antigenic analysis revealed that at neutral pH epitopes on the MPR are
unavailable. Upon low pH triggering and E2/E1 heterodimer dissociation the MPR
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became accessible to antibodies (81). In the post-fusion conformation the MPR again
became inaccessible and appears to pack on the trimer core aiding hairpin formation.
After further conformational change during hairpin formation the MPR epitopes again
became inaccessible (80, 81). Interestingly, neither E1 protein MPRs conserved length
nor any specific residue was required for membrane fusion, but large insertions or
deletions do decrease fusion (80).
The 42 amino acid VSV glycoprotein G MPR is absent from the solved crystal
structures of VSV G, but significant mutational analysis has been performed on the
region to inform its function (7). A significant degree of sequence homology exists
between the C-terminal regions of the vesciculoviruses suggesting a functional role for
this region. The MPR is hypothesized to stretch from the crown to the TMD in the VSV
G post-fusion structure (111). One hypothesized role for the MPR is as a flexible tether
to position VSV G properly between the viral and cellular membrane (110).
Additionally, there are mutation of conserved aromatic residues (W and F) singly or
together had little effect on cell-cell fusion. This is in contrast to tryptophan residues that
have been shown to be important in HIV-1 gp41 MPR fusion activity (63, 115). Further
mutational analysis identified significant reduction in cell-cell fusion and infectivity
when 13 residues (N449 to W461) of the MPR were deleted. Insertions also decreased
fusion activity and infectivity (63). These studies strongly support a role for the VSV G
in membrane fusion, but its specific function remains elusive.
Although the transmembrane domain and MPR are not included in the resolved
structures of pre- and post-fusion VSV glycoprotein G the fusion loops are mapped and
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the structure suggests they are in close proximity to the transmembrane region (111, 113).
One interpretation of these observations is that the MPRs simply functions as a flexible
tether from the transmembrane domain and allows the proper alignment of the fusion
protein with the membrane required for fusion to proceed (110). Alternatively, as
suggested above the MPR may play a role at the lipid interface to assist destabilizing of
membranes and promote lipid mixing (64, 129). Others have hypothesized a role for the
MPR to regulate fusion more directly, for example in HSV-1 gB the fusion loops may be
masked by the hydrophobic MPR preventing premature exposure to membrane (50).
As outlined above the MPRs of both class I and class II fusion proteins play a role
in cell-cell fusion. The lack of structural data for most MPRs limits our understanding of
the specific role the MPR plays in fusion. The MPR of class III VSV G is also important
for successful viral membrane fusion, but specific residues, such as tryptophan like gp41
have not been identified as critical to function. Analysis of HSV gB MPR, also excluded
from the crystal structure, may provide insight into gB specifically and class III fusion
proteins generally.
Structural data is not available for HSV gB MPR since the crystallized construct
was truncated just prior to the MPR at residue 730 (56). Exclusion of the MPR (731-773)
was due to the negative effect a highly hydrophobic region like the MPR can have on the
ability to crystal the protein (Figure I-9). Although there is no available structure of a
class III fusion protein MPR several studies have assessed its functional importance in
herpesvirus gB. While mutations in the HIV1 gp41 and VSV G MPRs do not disrupt
their expression and folding, the herpesvirus gB MPR appears sensitive to mutation
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resulting in defective protein folding and decreased cell surface expression (63, 82, 108,
115, 142, 149). Misfolding and low surface expression of mutants made it difficult to
assess the gB MPRs functional role. However, the few HSV gB MPR mutants that are
expressed on the cell surface are impaired in cell-cell fusion or virus entry (82, 142).
Generally, it is thought that in the pre-fusion form a fusion protein must mask its fusion
loops to prevent premature virus activation or interactions that would result in decreased
virus infectivity. In the post-fusion structure of HSV gB the fusion loops are not masked
by another portion of the solved structure, which does not include the MPR (56). In
contrast the fusion peptides of class I are protected within the trimer interface and fusion
loops of class II proteins are masked at the dimer interface (96, 145). Hannah et al. (50)
proposed that due to its hydrophobic nature the HSV1 gB MPR could mask the
hydrophobic fusion loops in the pre-fusion state. Interestingly, purified EBV gB
truncated to remove the C-terminus including the MPR self-associated forming rosettes
visible on electron microscopy (8). This association, presumably through the
hydrophobic fusion loops, supports the speculation that masking of these hydrophobic
fusion loops may prevent self-association or premature inactivation of fusion proteins.

Aims of present work
Each protomer of the gB trimer includes two fusion loops (a.a. 173-179
and 258-265) and a MPR (a.a. 731-773) (20, 49, 50, 56, 102, 108). The goal of my
dissertation has been to further define the role the gB fusion loops and MPR play in HSV
membrane fusion and its regulation. The construct used for gB crystallization lacked
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Figure I-9. gB membrane proximal region. (A) The amino acid sequence of the HSV
gB membrane proximal region (MPR). (B) Kyte-Doolittle hydropathy plot of gB
sequence. The signal sequence in demarcated by a box at the amino terminus of gB. The
putative MPR and TM domains are marked by black box. A positive peak greater then
1.6 indicates a high hydrophobicity score. (C) An expanded view of MPR/TM boxed
region in (B) showing a high hydrophobicity score. Web based Kyte-Doolittle calculator
web.expasy.org/protscale/ and Kyte and Doolittle (73).
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the MPR and the putative fusion loops were exposed with no mechanism to prevent
premature membrane interactions (56).
The forty-three amino acid MPR has a highly hydrophobic character and this
region was excluded from the crystalized gB construct due to its potential to decrease the
probability of successful crystal formation. In the second chapter of this dissertation
various gB MPR deletion and truncation mutants were constructed. The deletion
mutants, expressed in mammalian cells in a full-length gB background, were not
efficiently expressed on the cell surface. Next recombinant baculovirus expressed Cterminal gB MPR truncations were assayed for their membrane binding ability. I found
that despite the presence of fusion loops, purified soluble gB containing as few as the first
nine MPR residues (gB739t) was deficient in the ability to bind liposomes. In
comparison, gB(730t) lacking the entire MPR has been shown to bind liposomes (49).
Remarkably, mutation of two aromatic residues to alanine in the short nine amino acid
MPR was sufficient to restore the liposome binding ability of the soluble gB protein
(117). Together, these data suggest an important interaction within FR1 involving the
MPR that regulates liposome binding.
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CHAPTER 2

The membrane proximal region (MPR) of herpes simplex virus gB regulates association
of the fusion loops with lipid membranes

This chapter appeared as the published article “The membrane-proximal region (MPR) of
Herpes Simplex Virus gB regulates association of the fusion loops with lipid membranes”
by S. S. Shelly, T. M. Cairns, J. C. Whitbeck, H. Lou, C. Krummenacher, G. H. Cohen,
and R. J. Eisenberg. MBio. 2012 Nov 20; 3(6).
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ABSTRACT
Glycoprotein B (gB), gD, and gH/gL constitute the fusion machinery of herpes simplex
virus (HSV). Prior studies indicated that fusion occurs in a stepwise fashion whereby the
gD/receptor complex activates the entire process, while gH/gL regulates the fusion
reaction carried out by gB. Trimeric gB is a class III fusion protein. Its ectodomain of
773 amino acids contains a membrane proximal region (MPR, residues 731-773) and two
fusion loops (FL) per protomer. We hypothesized that the highly hydrophobic MPR
interacts with the FLs, thereby masking them on virions until fusion begins. To test this
hypothesis, we made a series of deletion, truncation, and point mutants of the gB MPR.
Although the full-length deletion mutants were expressed in transfected cells, they were
not transported to the cell surface, suggesting that removal of even small stretches of the
MPR was highly detrimental to gB folding. To circumvent this limitation, we used a
baculovirus expression system to generate four soluble proteins, each lacking the
transmembrane region and cytoplasmic tail. All retained the FLs as well as decreasing
portions of the MPR [gB(773t), gB(759t), gB(749t), gB(739t)]. Despite the presence of
the FLs, all were compromised in their ability to bind liposomes as compared to the
control, gB(730t), which lacks the MPR. We conclude that residues 731-739 are
sufficient to mask the FLs, thereby preventing liposome association. Importantly,
mutation of two aromatic residues (F732, F738) to alanine restored the ability of
gB(739t) to bind liposomes. Our data suggest that the MPR is important for modulating
the association of gB FLs with target membranes.
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INTRODUCTION
Herpes simplex virus (HSV) has four envelope glycoproteins that are essential for
virus entry into cells: gD, gH, gL, and gB. All herpesviruses use a combination of gB and
the heterodimer gH/gL to carry out fusion (9, 14, 16, 30, 41, 42); these three proteins are
considered the core fusion machinery. For HSV, an additional protein, gD, is part of this
machinery. Our current model of HSV fusion starts with the binding of gD to one of its
receptors, likely transmitting a signal to gH/gL, which in turn acts upon gB to trigger
fusion (3). HSV-1 gB is a 904 amino acid type I membrane glycoprotein whose crystal
structure identifies it as a class III fusion protein (23). Although there is no primary
sequence conservation, HSV-1 gB shares a high degree of structural homology with other
class III fusion proteins including vesicular stomatitis virus (VSV) G (46), baculovirus
gp64 (26), and Epstein-Barr virus (EBV) gB (5). According to ultrastructural data (5, 23,
26, 46), these presumed post-fusion conformations show that all are homotrimers with a
long central coiled coil structure reminiscent of class I fusion proteins. Yet, all have
internal bipartite fusion loops (FLs) which are similar to the single internal FL of class II
fusion proteins (14, 28, 31, 55). Single point mutations within either of the gB fusion
loops caused loss of cell-cell fusion and failure of soluble gB to associate with
membranes (20, 21).
For VSV G, ultrastructural data are available for both pre- and post-fusion forms
(46, 47) and indicate that the FLs are situated near the transmembrane region and are
close to the viral membrane in both forms. For the fusion loops to start and end in this
position, it is presumed that an intermediate step occurs where the fusion loops reposition
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to the top of gB to interact with the cellular membrane. Then, as gB changes
conformation to its post-fusion form, it pulls the viral and cellular membranes close
together to facilitate lipid mixing. The prevailing concept is that these hydrophobic loops
would be masked on the virus surface prior to fusion activation to avoid premature or
otherwise unwanted interactions that may be detrimental to virus infectivity.
The form of HSV gB used for crystallization ended at amino acid 730, leaving the
fusion loop region exposed (23). Residues downstream of amino acid 730 were initially
excluded for crystallization trials due to their elevated hydrophobicity, which could
impede crystal formation. These downstream residues (731-773) constitute the gB
membrane proximal region (MPR) (10, 23, 40, 43). The structure of the MPR remains
unknown for any of the class III fusion proteins but it seems likely to be in close
proximity to the FLs (Figure 2-1A).
MPRs provide essential functions in different types of fusion proteins. Mutations
within the MPRs of the fusion proteins for HIV (50), paramyxoviruses (57, 64), VSV
(24), and baculovirus (34) abolish fusion but do not affect cell surface protein expression.
MPRs are characteristically rich in aromatic residues (W, Y, F) (56) that have been
proposed to bridge the gap between the aqueous and hydrophobic environments present
at the lipid interface (29). These aromatic residues could also act in concert
(synergistically) with fusion peptides/loops to destabilize membranes and promote lipid
mixing (25, 56). Indeed, aromatic residues are also vital in FL function; it is presumed
that their side chains, along with their carbon backbones, are inserted into the target
membrane (37, 44, 46). Interestingly, the MPR of baculovirus gp64 does not contain any
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aromatic residues, but its bulky leucine residues appear critical for cell-cell fusion (34).
MPRs might also act as flexible tethers to help fusion proteins become properly
positioned between two lipid bilayers, as described for VSV G (45).
Several studies of gB from different herpesviruses highlight the functional
importance of its MPR. Most gB MPR mutants are defective in protein folding and cell
surface expression (35, 43, 58, 62), making it difficult to assess its functional role.
However, the few HSV gB MPR mutants that are expressed on the cell surface are
impaired in cell-cell fusion or virus entry (35, 58).
Previously, we suggested that the MPR could mask the hydrophobic FLs in the
pre-fusion state (21) in a way that would be analogous to how the FLs of class II fusion
proteins are masked at the dimer interface (18, 48, 61). Our goal here was to carry out a
systematic analysis of the MPR. We first made a series of MPR deletion mutants in this
region in full-length gB and expressed each mutant in mammalian cells. Unfortunately,
none of these mutants were efficiently transported to the cell surface, a defect previously
reported for other gB MPR deletions (43). We next constructed recombinant
baculoviruses to express C-terminal gB truncation mutants, containing various lengths of
the MPR. Despite the presence of the fusion loops, all of the proteins containing portions
of the MPR were compromised in their ability to bind liposomes as compared to the
MPR-less gB(730t), including gB(739t), which contains only nine MPR residues.
However, mutation of two aromatic residues in gB(739t) to alanine (F732A/F738A)
restored the ability of this protein to bind liposomes. Thus, our data are consistent with a
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critical role for the MPR in regulating exposure of the gB fusion loops thereby preventing
premature association with lipid.

MATERIALS AND METHODS
Cells. Mouse B78H1 melanoma cells engineered to express the gD receptor nectin-1
(C10 cells) were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 5% fetal bovine serum (FBS) and 500 µg/ml of G418. Chinese hamster ovary
(CHO-K1) cells were grown in Ham’s F-12 medium containing 10% FBS. CHO-K1 and
C10 cells were kindly provided by P. G. Spear. Sf9 (Spodoptera frugiperda) cells were
grown in Sf900II serum-free medium (Gibco).

Antibodies. Rabbit polyclonal antibodies (PAb) R68 and R69 were raised against fulllength gB1 purified from infected cells as previously described (19). gB-specific
monoclonal antibodies (MAbs) SS55 and DL16 were characterized previously and
recognize discontinuous (conformation-dependent) epitopes and are trimer-specific (6).

Plasmids. Full-length gB constructs containing deletions within the MPR, pSS1000
[gBD(730-747)], pSS1001 [gBD(748-773)] pSS1002 [gBD(730-739)], pSS1003
[gBD(735-744)], pSS1004 [gBD(740-749)], pSS1005 [gBD(750-759)], pSS1008
[gBD(765-773)], were created using the QuikChange XL site-directed mutagenesis kit
(Stratagene Cloning Systems) as described previously (11). QuikChange primers were
designed to “loop out” unwanted residues during amplification of template pPEP98
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(containing the full-length gB gene from KOS, a gift of P. Spear) (42) and were as
follows (deletion between underlined nucleotides, only forward primers shown):
pSS1000, 5’CATCCACGCCGACGCCAACGCCGCGGTCGGCAAGGTGGTGATGGGC;
pSS1001, 5’CGAGGGGATGGGCGACCTGGGGCGCCCCTTTGGGGCGCTGGCCGTGGG;
pSS1002, 5’-CACGCCGACGCCAACGCCGAGGGGATGGGCGACCTG; pSS1003,
5’-GCCGCCATGTTCGCGGGCCTGGGGCGCGCGGTCGGC; pSS1004, 5’GGCCTGGGCGCGTTCTTCGGCAAGGTGGTGATGGGC; pSS1005, 5’GACCTGGGGCGCGCGGTCGTGGTATCGGCCGTGTCG; and pSS1008, 5’GGCGGCGTGGTATCGGCCGTGCCCTTTGGGGCGCTGGCC. All deletions were
confirmed by sequencing the gB gene. Plasmids for expression of full-length HSV
glycoproteins (pPEP99, pPEP100, pPEP101) and those needed in the cell-cell fusion
assay (pCAGGS/MCS, pT7EMCLuc, pCAGT7) were gifts of P. G. Spear (39, 42).

Production and purification of soluble HSV glycoproteins. To construct a baculovirus
vector expressing the MPR-containing gB ectodomain, we PCR-amplified residues 526773 of gB1 from template pKBXX (containing the gB gene from KOS, a gift of S.
Person) using primers 5´-CGGCTGCAGTTTACGTACAA (PstI site underlined) and 5´CGCGAGTTCAATTGGACATGAAGGAGGACAC (EcoRI site underlined). This
fragment was cloned into PstI-EcoRI digested pCW289 (7) to generate pLH633
[gB(773t)]. Other truncations of gB1 were generated from template pLH633 by
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QuikChange mutagenesis, generating stop codons (underlined) at residues 740 (primer
5´-GGCCTGGGCGCGTTCTTCTGAATTCGGTACCGACTCTGC), 750 (primer 5´GACCTGGGGCGCGCGGTCTGAATTCGGTACCGACTCTGC), 760 (primer 5´GATGGGCATCGTGGGCGGCTGAATTCGGTACCGACTCTGC). The resulting
constructs were named pSS1010 [gB(739t)], pSS1013 [gB(749t)], and pSS1015
[gB(759t)], respectively. A double point mutant, gB-F732/738A(739t) (pSS1023), was
generated from template pSS1010 by QuikChange using primer 5´GCCAACGCCGCCATGGCCGCGGGCCTGGGC and 5´GCGGGCCTGGGCGCGGCCTTCGAGGGGATGGGC (substitutions underlined) to
sequentially add first F732A and then F738A to the coding sequence. All mutations were
verified by sequencing the entire gB gene. Recombinant baculoviruses were generated as
previously described (53). The resulting soluble gB proteins were puriﬁed with a DL16
immunosorbent column (7). Soluble gB-W174R(730t) was described previously (20).
Soluble gD(306t) was purified from baculovirus-infected insect cells as detailed
elsewhere (49, 53).

Western blotting. Purified, soluble proteins were mixed with an equal volume of 2X
sample buffer containing either no reducing agent and 0.2% SDS (“native” conditions) or
200mM dithiothreitol and 2% SDS (“denaturing” conditions) (13). Proteins from
denatured samples were also boiled for 5 min before electrophoresis. For full-length
proteins, C10 cells were grown on 6-well plates and transfected with the desired plasmids
according to the GenePORTER protocol (Gene Therapy Systems, Inc.). At 24-48 h post71	
  
	
  
	
  
	
  

transfection, cells were lysed in 200 mL of lysis buffer (10 mM Tris (pH 8), 150 mM
NaCl, 10 mM EDTA, 1% NP-40, 0.5% deoxycholic acid), 5 mL of which was used for
electrophoresis (denaturing conditions). All proteins were resolved by polyacrylamide
gel electrophoresis and transferred to nitrocellulose for Western blotting.

Fusion assay. To detect cell-cell fusion, we used a previously described luciferase
reporter assay (32, 39, 42). Briefly, CHO-K1 cells were grown in 24-well plates and
transfected with plasmids encoding T7 RNA polymerase (pCAGT7), gD (pPEP99), gH
(pPEP100), and gL (pPEP101) and either wild-type gB (pPEP98), mutant gB, or empty
vector (pCAGGS/MCS). To prepare receptor-expressing cells, CHO-K1 cells growing in
six-well plates were transfected with a plasmid encoding the firefly luciferase gene under
control of the T7 promoter (pT7EMCLuc) and a plasmid encoding HVEM (pSC386). Six
hours post-transfection, receptor-expressing cells were trypsinized and added to the
glycoprotein-expressing cells. At 18h post-cocultivation, cells were washed with PBS,
lysed in reporter lysis buffer (Promega), and frozen. Finally, the extracts were thawed and
mixed with 100 µl of luciferase substrate (Promega) and immediately assayed for light
output by luminometry.

CELISA. To detect gB cell surface expression, we used a modification of a cell-based
enzyme-linked immunosorbent assay (CELISA). CHO-K1 cells growing in 96-well
plates were transfected with pCAGT7, pPEP99, pPEP100, pPEP101, and a plasmid
encoding either wild-type gB (pPEP98), mutant gB, or empty vector (pCAGGS/MCS).
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Forty nanograms of each plasmid/well and 0.5 µl of Lipofectamine 2000 (Invitrogen)
were used. Cells were exposed to the DNA-Lipofectamine 2000 mixture for 5 h, after
which the mixture was replaced with growth medium. Cells were grown overnight, fixed
in 3% paraformaldehyde, and rinsed with PBS. Cells were then incubated for 1 h with
PAb R68 diluted in 3% bovine serum albumin-PBS and incubated for 30 min with goat
anti-rabbit antibodies coupled to horseradish peroxidase. Cells were rinsed with 20 mM
citrate buffer (pH 4.5), incubated with peroxidase substrate (Moss, Inc.), and the
absorbance at 405 nm was recorded using a microtiter plate reader. The absorbance
values of cells transfected with the empty vector pCAGGS/MCS was subtracted and data
were normalized to WT gB.

Liposome flotation assay. Liposome flotation assay conditions were adapted from
previously described methods (15, 20, 27). Liposomes were purchased from Encapsula
Nanosciences (Nashville, TN) at a size of 400 nm, containing a 1.7:1 molar ratio of soyphosphatidylcholine to cholesterol. Briefly, purified soluble gB (1 µg), liposomes (25
µg), 1x protease inhibitor cocktail (Roche), and 15 µl of 200 mM sodium citrate were
combined and the final reaction volume was adjusted to 50 µl with PBS. Proteinliposome mixtures were then incubated at 37°C for 1 h. To eliminate unwanted
electrostatic protein-lipid associations, mixtures were incubated with 1 M KCl for 15 min
at 37°C before being loaded at the bottom of a sucrose gradient. Mixtures were adjusted
to 40% sucrose in a final volume of 500 µl and overlaid with 4 ml of 25% sucrose-PBS
and 500 µl of 5% sucrose-PBS. The gradients were centrifuged for 3 h in a Beckman
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SW55Ti rotor at 246,000 x g at 4°C. Seven equal fractions (approximately 700 µl each)
were collected, starting from the top of the gradient. Dot blotting onto nitrocellulose was
performed using 225 µL per fraction and probed with the anti-gB PAb R68.

Surface plasmon resonance (biosensor) experiments to detect gB-liposome binding.
Surface plasmon resonance (SPR) experiments were performed using a Biacore 3000 or
Biacore X100 optical biosensor (GE Healthcare, Biacore Life Sciences) at 25°C. Filtered
and degassed HBS-N buffer (10 mM HEPES pH 7.4, 150 mM NaCl) was used in all
liposome association experiments. We used an L1 sensor chip (Biacore) as it has a
hydrophobic surface capable of binding liposomes. Liposomes were purchased from
Encapsula Nanosciences (Nashville, TN) at a size of 400 nm, containing a 1.7:1 molar
ratio of soy-phosphatidylcholine to cholesterol. To prepare the chip surface for liposome
binding, it was washed sequentially with 20 µl of 1% octyl-β-D-glucopyranoside, 20 µl
of 0.5% SDS, 10 µl of 1% octyl-β-D-glucopyranoside, and 10 µl of 30% ethanol.
Liposomes (1 mM, diluted in HBS-N) were injected until the chip was saturated, giving a
signal of approximately 8500 response units (RU). Once bound, the liposomes remained
on the chip and there was no appreciable dissociation (no measurable off-rate). Purified
soluble proteins diluted in HBS-N buffer were then individually injected at various
concentrations (achieved by dilution in HBS-N buffer) at a flow rate of 5 mL/min. After
injection of the soluble protein was complete (typically 20 mL for 240 s), the RU was
recorded and used to determine the level of protein binding. After each protein injection
the surface preparation protocol was performed to remove protein and liposomes from the
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chip, regenerating the surface to the RU baseline.

Gel filtration/ size exclusion chromatography. Size exclusion chromatography of gB
(52) was performed on a AKTApurifier equipped with a Superdex S200 (24 mL) column
(GE Healthcare) equilibrated with phosphate-buffered saline. The Superdex column was
calibrated by using thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa),
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), ribonuclease A
(14 kDa), and aprotinin (6 kDa); blue dextran was used to determine the void volume
(GE Healthcare). For each sample, 5 mL of each fraction was separated by SDS-PAGE
and the high molecular weight, trimeric, and monomeric forms of gB were visualized by
Western blotting with an anti-gB PAb (R68). Fractions that contained mostly
trimers/monomers were pooled and tested by SPR for liposome binding.

RESULTS
The crystal structure of HSV-1 gB (Figure 2-1A) was solved using a soluble form
of gB truncated at amino acid 730 (gB730t) (23) to avoid the hydrophobic membrane
proximal residues (730-773) just upstream of the transmembrane region (TMR) that
might impair crystal formation (10, 40). The form of HSV gB used for crystallization
ended at amino acid 730, leaving the fusion loop region exposed (23). Residues
downstream of amino acid 730 were initially excluded for crystallization trials due to
their elevated hydrophobicity, which could impede crystal formation. We hypothesized
that these 43 amino acids, constituting the membrane proximal region (MPR) of gB,
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obscure the fusion loops and prevent them from interacting with a target membrane until
gB is “activated” for fusion (21). We assumed that these residues are in close proximity
to the fusion loops based on the gB crystal structure (Figure 2-1A, yellow).

MPR deletions impair HSV gB transport. To determine if the MPR regulated the
ability of the fusion loops to associate with membranes, we first constructed seven MPR
deletion mutants (within the context of full-length gB) (Figure 2-1B). The N-terminal
half of the MPR was deleted in gBD(730-747) and the C-terminal half was deleted in
gBD(748-773). The remaining mutants contained smaller deletions spanning the MPR:
gBD(730-739), gBD(735-744), gBD(740-749), gBD(750-759), and gBD(765-773). All
mutants were efficiently expressed in B78-C10 cells, as seen by Western blots of total
cell lysates (Figure 2-2A). However, when intact transfected cells were tested by
CELISA, all of the deletion mutants were poorly expressed (<30% that of gB-WT) on the
cell surface, indicating that although the mutants were expressed they were inefficiently
transported to the cell surface (Figure 2-2B, black bars). Consequently, none were able
to function in a cell-cell fusion assay (Figure 2-2B, gray bars). Thus, as seen in other
studies (43, 62), deletion of even small sections of the gB MPR has a negative impact on
proper protein folding and transport.

Construction of soluble, MPR-containing gBs. To characterize the biochemical
properties of the gB MPR, we created and purified a series of soluble gB ectodomains (no
TMR or endodomain) that lack portions of the MPR. We previously characterized the gB
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Figure 2-1. (A) Surface representation of the gB trimer. Residues of FL1 (from all 3
monomers) are shown in pink while those of FL2 are shown in blue. The C-termini of the
solved gB monomers are highlighted (yellow). The unsolved MPRs (amino acids 730773) of each protomer are represented as dashed, tan lines emanating from the gB
monomer C-termini. FL1 and FL2 of one protomer are labeled in the bottom view of the
trimer. (B) Stick figure of a gB protomer, showing its structural domains (Roman
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numerals). FL1 and FL2 are indicated with arrows, colored as in (A). Amino acid
numbers are shown along the top. The MPR is highlighted in tan and its residues are in
expanded view below. Residues that were mutated in this study are highlighted in bold
and starred. Deletion mutants are designated as boxes and aligned below the MPR amino
acids, with a dashed line indicating deleted residues in the full-length protein. (C) Stick
representation of the soluble C-terminal truncation mutants generated in this study. The
point mutations F732A and F738A are indicated as black bars. Sig, signal sequence.
TMR, transmembrane region.
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ectodomain gB(730t), lacking all of the MPR, and found that it remains oligomeric,
retains all of its major epitopes, and associates with liposomes (12, 20, 23). Here, we
compared it with both soluble forms of gB bearing partial MPRs [gB(759t), gB(749t),
gB(739t)] and a complete ectodomain containing the full MPR, gB(773t) (Figure 2-1C).
All were expressed and secreted into the supernatant of baculovirus-infected cells (Figure
2-3A). When the proteins were examined on a non-denaturing gel, all contained both
monomeric and trimeric forms of gB (Figure 2-3A, bottom panel). Although all of the
truncated proteins were recognized by MAbs with trimer-specific, conformationdependent epitopes (DL16, SS55), indicative of proper protein folding, gB(759t)
appeared to react less well (Figure 2-3B). All MPR-containing gBs also retained their
ability to react with MAbs with epitopes in each functional region (data not shown).

Presence of the MPR affects binding of soluble gB to liposomes.
(i) Analysis by liposome flotation. We previously observed that the MPR-less
soluble gB(730t) interacts in vitro with liposomes when the two are mixed (12, 20),
presumably recapitulating the interaction of the gB fusion loops with the cell membrane
during virus-cell fusion. Initially, we used the liposome flotation assay to assess whether
the MPR, or portions of it, interfered with this interaction. Purified soluble proteins were
individually incubated with liposomes (phosphatidylcholine-cholesterol) at 37oC. Each
protein-liposome mixture was then adjusted to 40% sucrose, layered beneath a sucrose
step gradient and centrifuged to allow the liposomes and any associated proteins to float
to the top, while proteins that failed to bind liposomes would remain at the bottom of the
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Figure 2-2. Characterization of gB MPR deletion mutants. (A) Full-length MPR
mutants were expressed in mammalian cells and total cell extracts were analyzed by
denaturing Western blot. Blots were probed with the anti-gB PAb R68. (B) Protein
surface expression as detected by CELISA (black bars). Transfected CHO-K1 cells were
fixed with 3% paraformaldehyde, then incubated with the anti-gB PAb R69 and GAMHRP. Cells transfected with empty vector DNA were used as a negative control, and this
value was subtracted from the other experimental samples. Quantitative cell-cell fusion
assay (gray bars) was performed with co-cultivation of target CHOK1 cells (expressing
the luciferase protein and the HSV receptor HVEM) with effector CHO cells (expressing
T7 polymerase, gD, gH and gL, plus either WT gB, mutant gB, or empty vector DNA).
Cell extracts were tested for light production 18 h later. Percent WT was calculated as
follows: for CELISA = (sample absorbance / WT absorbance) x 100; for fusion assay =
(relative light units (RLU) of test sample/ RLU of WT) x 100.
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gradient. The liposome-containing (top) fractions were analyzed by dot blot using a
polyclonal anti-gB antibody for visualization (Figure 2-3C). As previously observed
(20), gB(730t) was not detected in the upper fractions in the absence of liposomes, but
floated to the top of the gradient in their presence. In the case of the MPR-containing
gBs, the ability to co-associate with liposomes decreased markedly. The data shown in
Figure 2-3C suggests there might be a small difference in binding between gB(739t) and
gB(773t) but this type of analysis is not quantitative. Therefore, we turned to surface
plasmon resonance (SPR, biosensor) to get a more accurate measurement of liposome
binding (8).

(ii) Analysis by SPR/biosensor. Liposome are able to bind to the lipophilic L1 chip of
the Biacore instrument, which detects mass changes by SPR (1). In this assay, liposomes
were first injected and flowed across an L1 chip surface and liposome binding, i.e. the
mass change due to binding, was detected as an increase in response units (RU) (Figure
2-4A). Approximately 8500 RU of liposomes were sufficient to saturate each flowcell of
the chip and this amount was used in each experiment. Next, each gB protein was added
and allowed to flow across the chip for 240 s. An increase in RU was indicative of
protein binding to the immobilized liposomes. It is this second response curve (gBliposome binding, Figure 2-4A, framed) that is shown in Figs. 4B-E. To set up the
appropriate binding conditions for our proteins, we first compared gB(730t), known to
bind liposomes in a flotation assay, to both the fusion loop mutant gB-W174R(730t) and
to gD(306t), two proteins which do not bind liposomes (20). As expected, gB(730t)
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Figure 2-3. Soluble gB MPR-containing proteins are expressed and folded correctly.
(A) Four gB mutants (739t, 749t, 759t, 773t) were cloned and expressed in a baculovirus
expression system as secreted forms each truncated after the indicated amino acid.
Proteins were detected with the PAb R69 and visualized by denaturing (top panel) or
“native” (bottom panel) Western blot. (B) Reactivity of gB MPR-containing proteins
with the conformation-dependent MAbs SS55 (top panel) or DL16 (bottom panel) via
“native” Western blot. Molecular weight standards are shown on the left in kilodaultons
for both (A) and (B). (C) Liposome flotation assay. Purified soluble glycoproteins were
incubated with liposomes for 1 h at 37oC. Samples were then adjusted to 1M KCl,
incubated for an additional 15 min and then layered beneath a discontinuous 5-40%
sucrose gradient, centrifuged for 3 h, and then fractionated. The top, liposome-containing
fraction was analyzed by dot blot with the PAb R68.
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readily bound to the immobilized liposomes, as indicated by the increase in RU, while
gB-W174R(730t) and gD(306t) did not (Figure 2-4B). Furthermore, gB(730t) bound to
liposomes in a dose-dependent manner, showing an increase in RU from 0.08 mM to 5
mM of protein (Figure 2-4C). Thus, we demonstrated that biosensor analysis yields
reproducible and quantitative data on membrane binding by soluble glycoproteins.
The liposome binding capacity of the MPR-containing gB forms was then
analyzed within the same range of protein concentrations as used for gB(730t). We
found that gB(773t), which contains the complete MPR, bound to liposomes in a dosedependent manner, albeit at a much lower level than seen for gB(730t) (compare Figure
2-4C and 2-4D). Although, curve-fitting for kinetic analysis (1) was not possible with
our data sets, possibly due to complications associated with liposome binding. None of
the MPR-containing gB truncations bound to liposomes as well as gB(730t), although all
exhibited a low level of measurable binding (Figure 2-4E), especially when compared to
the two negative controls (Figure 2-4B). Of importance, we detected no significant
differences in gB-liposome binding between proteins containing portions of or the
complete MPR [gB(739t), gB(749t), gB(759t), or gB(773t)]. Upon averaging the
maximum binding from several experiments (i.e. after two minutes of injection of 0.16
mM gB) we determined that gB(739t) bound to liposomes at a level that was 35% of that
of gB(730t), gB(749t) 38%, gB(759t) 29%, and gB(773t) 46% (Figure 2-4F). In
comparison, the negative control gB-W174R(730t) bound at 18% that of gB(730t). The
data show that the presence of the first nine amino acids of the MPR (residues 731-739)
are sufficient to significantly diminish the association of gB with liposomes.
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Figure 2-4. Liposome binding assay, biosensor analysis. (A) Liposomes are injected
and flowed across flowcell (Fc) 1 and Fc2, with binding at saturation [~8500 RU
(response units)]. Soluble gB(730t) is then injected across Fc2 at 5 mL/min for 240 s and
binding to liposomes is measured as an increase in RU; this portion of the graph (boxed)
is shown and analyzed in subsequent figures. A double-slash denotes a break in the x-axis
(no injections were performed during that time period). (B) Response curve showing
binding of control proteins gB(730t) (positive control), fusion loop mutant gBW174R(730t) (negative control), and soluble gD (negative control). Two-fold serial
dilutions of gB(730t) (C) or gB(773t) (D) were injected across the liposome-coated flow
cell at 10 µl/min for 2 minutes to evaluate ligand-liposome association. After each
injection the surface preparation protocol was performed to remove protein and
liposomes from the chip, regenerating the surface to the RU baseline. (E) Each soluble
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protein (156 nM) was flowed across an L1 chip containing immobilized liposomes as
described in (A). Flow rate was 5 mL/min. (F) Bar graph representation of gB-liposome
binding via biosensor. The graph displays an average of at least 3 separate experiments,
with samples presented as percent binding of gB(730t) (set at 100%). Error bars
represent percent error.
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The decrease in liposome binding is not due to aggregation of the MPR mutants.
Our data suggest that the MPR specifically obscures the fusion loops and prevents their
interaction with lipids; however, another possibility is that the hydrophobic character of
the MPR promotes gB aggregation, possibly obscuring the fusion loops non-specifically
and preventing binding to membranes/lipids. To address this issue, we used gel filtration
to separate out any high molecular weight (HMW, i.e., aggregated) gB species from those
fractions predominantly containing gB trimers (Figure 2-5, left panels). We then tested
the pooled trimeric fractions for liposome binding using SPR (Figure 2-5, right panels).
Each protein was chromatographed by size exclusion on a sepharose column as
previously described (52). Multiple fractions were obtained and evaluated by Western
blotting and a representative group of data is shown in Figure 2-5. The bulk of gB(730t)
eluted in the trimeric fractions (boxed in Figure 2-5A) and much less was found in the
earlier, HMW fractions. In contrast, the bulk of the MPR-containing gBs (represented by
gB(749t) in Figure 2-5B) was in the HMW fractions (Figure 2-5B and data not shown).
For each protein, the trimeric fractions were pooled and equal concentrations of protein
were injected over the liposome-L1 chip. As expected, the trimeric pool of gB(730t)
bound well to liposomes (Figure 2-5A, right panel). Importantly, the trimeric pools of
MPR-containing gBs were unable to bind liposomes, as exemplified by gB(749t) (Figure
2-5B). Indeed, the modest binding of unfractionated gB(749t) was substantially reduced
by removal of the HMW material, suggesting that its binding was due to non-specific
association of aggregated material. Together, our results indicate that aggregation of
MPR-containing gB does not prevent liposome binding, but instead indicate that MPR86	
  
	
  
	
  
	
  

Figure 2-5. Gel filtration/size exclusion chromatography of (A) gB(730t) and (B)
gB(773t). Fractions containing mostly trimeric (boxed in the Western blot) species were
tested via biosensor for liposome binding at 156nM gB for 240 s. Fractions containing
high molecular weight species (HMW, samples to the right of the box on the Western
blot) were excluded from study. “Total” refers to the gB sample before it underwent gel
filtration.
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containing gB trimers are specifically compromised in their liposome-binding ability as
compared to gB(730t), presumably due to the FLs being obscured by the MPR.

A double point mutation within the MPR restores gB-liposome binding. Because
mutants such as gB-W174R(730t) do not bind liposomes (Figure 2-4B), it is clear that
association of gB(730t) with lipid membranes occurs via its fusion loops (20). Here we
have shown that the first nine residues of the MPR are sufficient to reduce this binding
(Figure 2-4E-F). Among residues 731-739 (MFAGLGAFF) there are four hydrophobic
amino acids: F732, L735, F738, and F739. These residues could stabilize the MPR and
through their side chains possibly form contacts with the fusion loops or surrounding
residues. To address the role of these nine residues, we selected F732 and F738, as based
on our model they were most likely to form such contacts (Figure 2-6A), and mutated
them to alanine, creating a double point mutant within the context of gB(739t), gBF732/738A(739t) (Figure 2-1C). We predicted that this mutant would prevent putative
interactions between the MPR and the underlying residues of the fusion loops (modeled
in Figure 2-6A) and therefore might improve gB-liposome binding in the context of
gB(739t). The mutant protein was recognized by MAbs against conformation-dependent
epitopes, indicating that it was properly folded (Figure 2-6B). Unlike its parent protein
gB(739t), very few HMW species were observed when gB-F732/738A(739t) was
analyzed by gel filtration (Figure 2-6C). Interestingly, biosensor analysis revealed that
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gB-F732/738A(739t) bound liposomes much better than gB(739t) and nearly as well as
gB(730t) (Figure 2-6D). These data suggest that the phenylalanine mutations
compromise the ability of the MPR to shield the fusion loops, permitting their exposure
and subsequent association with lipid membranes.
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Figure 2-6. (A) Model of a possible interaction between the gB fusion loops and MPR.
The gB trimer is rendered in cartoon form in gray, focusing on the fusion loops (FL1
pink, FL2 blue) and C-terminus of one of the protomers (H724, yellow spheres). Sidechains of both fusion loops are shown. The MPR is depicted as a gold dashed line, with
the aromatic residues F732 and F738 represented as circles. (B) Native Western blot of
soluble gB proteins, probed with the indicated MAbs. Molecular weight standards are
shown between the two blots in kilodaultons. (C) Native Western blot of gel filtration
fractions as described in Figure 2-5. (D) gB-liposome binding assay (biosensor analysis)
as described in Figure 2-4A. Soluble gB(730t) served as the positive control and soluble
gD as the negative control.
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DISCUSSION
Both class I and class II viral fusion proteins have their fusion peptides/loops
buried inside the molecule in the pre-fusion form (59). Here, we suggest that for the class
III fusion protein HSV gB, the MPR serves this role. Soluble gB ectodomains containing
various lengths of the MPR were all reduced in liposome binding as compared to the
MPR-less gB(730t); this included gB(739t), which contains only nine MPR residues.
Mutation of two phenylalanine residues to alanine (F732A/F738A) in the gB(739t) MPR
sequence restored the ability of this protein to bind liposomes. We believe that
substitution of alanine residues for F732 and F738 disrupts the association of the MPR
with the fusion loops, thereby allowing the fusion loops to be unimpeded and now able to
bind lipid membranes. Our data are consistent with a role for the MPR in regulating the
lipid association capability of the gB fusion loops.

Use of biosensor to evaluate gB-liposome binding. To study gB-liposome interactions,
we used SPR/biosensor in addition to our previously described liposome flotation assay
(12, 20). SPR has been used in the HIV field to dissect antibody-MPR (of the viral
fusion protein gp41)-liposome binding (reviewed in (22)). Here we have applied it to the
HSV fusion protein, gB. Since liposomes remain as individual vesicles when bound to an
L1 sensor chip (2), as they do with liposome flotation, the two assays should be in
agreement to measure protein-liposome interactions. Measuring liposome binding by
SPR has several advantages over the standard flotation assay. First, it is far easier and
faster to measure binding, as multiple samples can be analyzed on a single chip.
91	
  
	
  
	
  
	
  

Moreover, SPR allows for real-time measurement of gB-liposome binding whereas the
flotation assay relies on a secondary observation (antibody binding on a dot or Western
blot) taking place approximately 6 hours after the proteins and liposomes are coincubated. The quantitative nature of the biosensor also allowed us to compare percent
binding of each experimental sample to wild type [in this case, MPR-containing gBs, gB
fusion loop mutants, or gD to gB(730t)].

The HSV gB MPR is sensitive to mutation. Unlike the MPRs of other fusion proteins
(24, 34, 50, 57, 64), the MPR of gB is particularly sensitive to deletion (43) (Figure 2-2).
While our data point to MPR residues 731-739 as having a role in modulating fusion, the
remainder of the MPR remains essential at the very least for protein folding and
transport; this may be due to hydrophobic residues in the FLs or the MPR being
recognized by ER chaperones, leading to ER retention. While deletions within the gB
MPR are detrimental in the context of full-length proteins, deletion of the MPR in soluble
gB ectodomains does not affect protein expression in our baculovirus system (nor does
inclusion of the MPR). Although the soluble gB ectodomain is believed to be in a postfusion form, we are hypothesizing that the MPR functions as a fusion loop “mask” even
when gB is in a pre-fusion form prior to fusion. In fact, a pre-fusion structure of VSV G
(47) and model of EBV gB (5) suggest that structural domain I, which contains the fusion
loops, remains in the same relative conformation both pre- and post-fusion, suggesting
that this strategy is sound. In further support, the FLs remain in close proximity to the
ectodomain C-terminus (and therefore MPR) in both pre- and post-fusion forms.
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Previously characterized MPR point mutants in full-length HSV-1 gB were found
to be complementation-defective for gB-null virus and exhibited a slower rate of entry,
although two of the four mutants characterized were also defective in protein trafficking
(58). None of these point mutants were within residues 731-739, which we have defined
as having an effect on liposome binding. In additional experiments, we found that
separate mutation of F732A or F738A (in the context of full-length gB) had no effect on
cell surface expression yet each had a negative effect on cell-cell fusion (data not shown).
This result is in accordance with our data from the soluble gB-F732/738A double mutant.
We predict that the decrease in cell-cell fusion would be explained by premature
“triggering” of the FL, due to disruption of important MPR contacts required to maintain
gB in a pre-fusion form. It is of note that gB residue F738 is conserved in all
alphaherpesviruses (23, 58).

Role of the MPR in other viruses. MPR mutations in both VSV G (24) and baculovirus
gp64 (34) abolish fusion but do not affect cell surface protein expression, indicative of a
role for the MPR in the function of these proteins. In the VSV G, the amino acids
upstream of the TMR in the linear sequence are modeled as “stretching” from the top of
the protein structure (crown) down to the transmembrane region in the post-fusion
structure (46), and this region is hypothesized to act as a flexible tether for positioning of
the fusion protein between the viral and cellular lipid bilayers (45). Unlike the gB fusion
loops, those of baculovirus gp64 are hypothesized to have a second role, in virus-cell
attachment (26, 63). Therefore, one would expect the triggering of gp64 fusion loops
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would occur earlier in the pathway (to facilitate virus-cell attachment) than for gB (to
initiate virus-cell fusion), leaving the MPRs of gp64 and gB to perhaps serve different
functions.

How might the gB MPR and FLs work together? There are several hypotheses on
what triggers gB activation, thereby exposing the fusion loops and promoting fusion of
the virus and cell membranes (59). A low pH, “histidine switch” model has been
proposed for gp64 (33) and was also tested for HSV gB by Heldwein and colleagues (54),
who found that only one of the two fusion loops (FL2, containing H263) changed
conformation at low pH; the bulk of the soluble gB(730t) remained unchanged in
structure. Although this work was done on soluble gB (thought to be in the post-fusion
conformation), it fits with a pre-fusion model of EBV gB which predicts that domain I
(containing the FLs) retains its fold between pre- and post-fusion forms (5). Therefore,
we suggest that the change in FL2 in response to low pH is sufficient to disengage the
FLs from the MPR and expose them to lipids. Indeed, when gB(739t) was incubated at
pH 5, its ability to bind liposomes increased to 68% that of gB(730t) (data not shown).
However, we need to keep in mind that HSV gB also functions at neutral pH in certain
cell types (17, 36, 38, 60) and activation may occur through gHgL-gB interactions (3, 4),
and perhaps even the gB cytoplasmic tail (51). Regardless of these possibilities, our data
highlight the importance of the MPR in regulating exposure of the gB fusion loops and
suggest they play a critical role in maintaining gB in an inactive form, i.e. unable to insert
its fusion loops into a target membrane until it is triggered to execute virus-cell fusion.
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CHAPTER 3
GENERAL DISCUSSION
HSV entry is a highly regulated process that requires four viral glycoproteins; gD,
gH/gL heterodimer, and gB (8, 11). The crystal structures of these core fusion
components have been solved and provide detailed information about their structure and
function, but much work still needs to be completed to fully understand the HSV entry
process (4, 5, 12, 14). The gB MPR was not included in the crystallized gB construct
[gB(730t)], so its structural organization is not known (12). In this thesis I investigated
the role of the gB MPR in the function and regulation of fusion.
As described in Chapter 2, using a series of gB deletions, truncations, and point
mutations we found that the presence of as few as nine MPR residues [gB(739t)] resulted
in a decrease in gB’s ability to associate with liposomes. We also found mutation of two
aromatic residues in gB(739t) to alanine (F732A/F738A) restored liposome binding. In
comparison, MPR-less gB [gB(730t)] bound liposomes well via its fusion loops as was
observed in our lab’s previous work (10). These data are consistent with a critical role
for the MPR in regulating exposure of the gB fusion loops, thereby preventing premature
association with lipid.
Analysis of the gB ectodomain crystal structure suggests it represents the postfusion form of the fusion protein based on structural homology with the VSV G postfusion structure (12, 17-19). Interestingly, in the VSV G pre-fusion and post-fusion
structures the FL containing domain undergoes little intra-domain conformational
rearrangement. In both the pre-fusion and post-fusion structures the VSV G fusion loops
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remain exposed and appear accessible to interact with membranes while the entire
domain maintains its overall structure (17-19). Given the structural homology between
post-fusion structures of the class III fusion proteins VSV G and HSV gB, we
hypothesized that VSV G could be used to model and predict the HSV gB pre-fusion
structure. A similar approach was used to create a hypothetical model of pre-fusion EBV
gB, but this model has not yet been verified by a pre-fusion EBV gB crystal structure (3).
A hypothetical HSV gB pre-fusion organizational model was proposed by John Gallagher
and J. Charles Whitbeck in our laboratory (Figure 3-1A). This model predicts the general
conformational changes from HSV gB pre-fusion to post-fusion through a pre-hairpin
intermediate (Figure 3-1).
The class III fusion protein VSV G’s pre-fusion structure revealed exposed fusion
loops (19). We hypothesize that HSV gB, and as noted in the previously published
model of EBV gB, pre-fusion structures are similar to VSVG, and they will also have
exposed fusion loops (3, 17, 19, 22). This is in contrast with the internally buried fusion
peptides/loops of class I and class II fusion proteins.
Our proposed pre-fusion gB model lacks the MPR (Figure 3-1A), as the gB postfusion structure does, but we hypothesized in chapter 2 that the HSV MPR functions to
“mask” the fusion loops from premature exposure to membrane (Figure 2-6A). MPR
masking of the gB FLs adds another potential layer of regulation to already the complex
HSV entry process.
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Figure 3-1. Model of conformational changes predicted to occur between the pre-fusion
and the post-fusion forms of HSV gB. (A) Shows the pre-fusion form of gB modeled
after the published pre-fusion form of VSV G. (B) and (C) depict changes predicted to
occur as structural domain 1 (blue; including the fusion loops) disengages from the MPR
(not shown) and extends toward the target (host) cell membrane. Arrows indicate
direction of movement. (D) shows the fully extended (pre-hairpin) intermediate. Here
the fusion loops are predicted to insert into the target membrane. (E) represents the postfusion structure of gB based on the published crystal structure. Figure provided by John
Gallagher and J. Charles Whitbeck.

107	
  
	
  
	
  
	
  

Regulation of the gB transition from pre-fusion to post-fusion resulting in
membrane fusion must require an activation trigger leading to FL exposure. In chapter 2
we suggest a low pH “histidine” switch model as described by Stampfer et al. (21)
resulting in a shift in FL2 disengaging the MPR and exposing the FL for membrane
interaction. This low pH model is attractive due to the FL2 conformational change noted
above, but it does not fit all HSV entry situations. Since HSV does not require low pH to
enter all cell types, as described in the introduction, another mechanism is needed for gB
activation. The interaction between gB and gH/gL could serve to induce a conformational
change in gB that releases the MPR from the FL allowing cellular membrane binding and
initiation of fusion reaction (1, 2).
After gB activation and FL exposure the predicted conformational changes
proceed from the pre-fusion form through an extended pre-hairpin intermediate to folds
to the solved post-fusion gB structure pulling the viral and cellular membranes together
(Figure 3-1). Our proposal includes global rearrangements of the gB domains in relation
to each other and few changes within domains themselves. Interestingly, in response to
low pH the class II fusion protein TBEV E also undergoes large movements of domains,
but few conformational changes occur within the individual domains during transition
from a dimeric state to a trimeric post-fusion state. Many conclusions can be drawn
through analysis of our biochemical assays, functional assays, and comparative fusion
protein analysis. Ultimately, HSV gB’s ability to facilitate membrane fusion will be best
understood by evaluation of a pre-fusion structure, and hopefully intermediate structures
as well.
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Future directions
In this thesis the role of the MPR has been investigated to provide insight into the
regulation and exposure of gB FLs. Not surprisingly this work has generated many new
questions. To answer these questions a continuation of the detailed analysis of the
interaction between the MPR and the FLs is needed. Using our biochemical and
functional assays in combination with an expanded array of MPR and FL mutations we
may be able to further identify key interactions between the MPR and FLs. The further
refinement of the gB MPR interaction with the FLs may reveal important steps in the
regulation of gB-membrane interactions and fusion mechanism.
Arguably the greatest future insight into gB function would be delivered by the
capture of a pre-fusion structure. Inclusion of the MPR into this structure would be ideal,
but give the high hydrophobicity that prompted the MPRs exclusion from the post-fusion
structure its inclusion is unlikely (12). Lacking global gB structural data we could build
more modestly on our MPR structural knowledge using long peptides encompassing the
MPR sequence for crystallization and structural analysis as was performed for HIV-1
gp41 MPER (15, 20). Using a variety of techniques including circular dichroism, cryoelectron microscopy, SPR we may determine further details of the gB MPR structure and
function by analyzing a MPR peptide.
To continue the investigation of gB in the absence of a pre-fusion structure we
have initiated the development of a series of polyclonal antibodies to the gB MPR and
FLs. These reagent could provide a wealth of information about the accessibility and
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functional interactions between the FLs and MPR during the fusion process. Few
neutralizing antibodies to viral fusion loops/peptides have been identified, but several
reports in Dengue virus and related flaviviruses have identified a neutralizing antibody
that maps to their fusion peptides (6, 7). We have preliminary data that support the
successful development of a polyclonal antibody to the HSV FLs (data not shown).
Similarly, MPR specific antibodies have rarely been reported. In the HIV-1 gp41
neutralizing antibodies that map to the MPER (membrane proximal external region) have
been identified in several patients. Analysis of these neutralizing antibodies has
expanded the understanding of gp41s role in fusion and lipid interaction (9, 13, 16).
Development of an antibody against the HSV gB-MPR could provide a wealth of
information leading to a better understanding of the MPRs interaction, structure, and
function.
Finally, future analysis of FLs and MPR needs to be evaluated in context of the
entire HSV entry complex. Given HSV’s requirement for four glycoproteins gD, gH/gL,
and gB, for both entry and virus-induced cell fusion, the continued dissection of this
mechanism will be a continuing challenge. Ultimately, the detailed structural and
functional understanding of HSV entry will have long-range implications contributing to
the framework for future therapeutics and vaccine development across the herpesvirus
families.
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APPENDIX

Autophagy is an essential component of Drosophila immunity against
vesicular stomatitis virus

Reprinted from Publication Immunity, 30(4), S. S. Shelly, N. Lukinova, S. Bambina, A.
Berman, S. Cherry, Autophagy is an essential component of Drosphila immunity against
vesicular stomatitis virus, 588-598, Copyright (2009), with permission from Elsevier.
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ABSTRACT
Intrinsic innate immune mechanisms are the first line of defense against pathogens and
exist to control infection autonomously in infected cells. Here, we showed that
autophagy, an intrinsic mechanism that can degrade cytoplasmic components, played a
direct antiviral role against the mammalian viral pathogen vesicular stomatitis virus
(VSV) in the model organism Drosphila. We found that the surface glycoprotein, VSVG, was likely the pathogen-associated molecular pattern (PAMP) that initiated this cellautonomous response. Once activated, autophagy decreased viral replication, and
repression of autophagy led to increased viral replication and pathogenesis in cells and
animals. Lastly, we showed that the antiviral response was controlled by the
phosphatidylinositol 3-kinase (PI3K)-Akt-signaling pathway, which normally regulates
autophagy in response to nutrient availability. Altogether, these data uncover an intrinsic
antiviral program that links viral recognition to the evolutionarily conserved nutrientsignaling and autophagy pathways.
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INTRODUCTION
Detection and clearance of viruses by the innate immune system relies on several
distinct and essential pathways that are evolutionarily conserved (18). Extracellular
virions are recognized via Toll-like receptors present on the cell surface and within
endolysosomal compartments. These receptors were first identified in Drosphila and are
now recognized as the canonical pathogen recognition system in all metazoans (53).
Cytoplasmic pattern recognition receptors, originally identified in plants (36), also act as
intracellular pathogen detectors. Yet another intracellular pattern recognition system
responsible for the degradation of viral dsRNA genomes or replication intermediates is
the RNA interference (RNAi) pathway (31). Recently, autophagy, another ancient and
conserved intracellular pathway, has also been implicated in innate immunity and
pathogen destruction ((16), (21), (30), (34), (39) and (44)).
Autophagy was first genetically characterized in yeast as a response to starvation
and is the process by which cells degrade cytoplasmic components, including organelles
for recycling ((23), (24), (25) and (38)). Macroautophagy, which will be referred to as
autophagy throughout this article, occurs through the de novo formation of doublemembraned vesicles called autophagosomes that envelop cytoplasmic regions, which
mature and grow, and subsequently fuse with the lysosome for degradation of the
internalized cytoplasmic contents. Autophagy is involved in a plethora of processes,
including the removal of damaged organelles and intracellular protein aggregates,
turnover of long-lived proteins, and cell death (37). Autophagy is required both for
normal development and survival from nutrient depravation. For these processes, it has
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been shown that autophagy is controlled by the phosphatidylinositol 3-kinase (PI3K)Akt-signaling pathway. Activation of the signaling pathway inhibits autophagy, whereas
the loss of signaling through this cascade relieves the negative repression of target of
rapamycin (TOR) kinase on Atg1, an essential upstream component of the autophagy
pathway (51). Therefore, there is a direct link between nutrient availability and
autophagy.
In mammalian systems, autophagy was recently shown to be important in innate
immune defense against intracellular pathogens (30). Studies on bacterial pathogens have
revealed that some bacteria are cleared from the cytoplasm by autophagy ((2), (16), (33),
(39), (40) and (50)). There have also been studies implicating autophagy in antiviral
defense. For example, many viruses can be observed inside of autophagic compartments,
including herpes simplex virus 1 (HSV-1) and Sindbis virus ((49) and (52)). Moreover,
data suggest that beclin 1 (the human homolog of Atg6), perhaps via autophagy, restricts
viral encephalitis induced by both HSV-1 and Sindbis ((32) and (41)). In plants,
autophagy prevents the spread of cell death during the hypersensitive response, which
restricts viral replication (34). However, it has not been established that autophagy itself
is sufficient to control the replication of these viruses or whether there are other facets of
activated pathways, such as cell death, that are affecting viral growth. Given the
potentially critical role of autophagy in defending from infection and the fact that little is
known about intrinsic antiviral mechanisms, we set out to determine whether autophagy
can directly control viral replication in the genetically tractable organism Drosphila
melanogaster. Drosphila has no acquired immune system, relying only on innate systems
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to combat pathogens ((10) and (28)). This simplified immune system allows us to test the
role of innate factors in isolation. Here, we showed that autophagy controlled vesicular
stomatitis virus (VSV) replication in both cultured Drosphila cells and adult flies. VSV
infection via the surface glycoprotein was sensed by flies, and this, in turn, activated
autophagy independently of viral replication. Increased autophagic activity was mediated
by repression of the nutrient-signaling cascade, which alleviated repression of autophagy,
activating the antiviral program. This pathway was critical to the control of viruses
because the loss of autophagy converts a nonpathogenic VSV infection into a lethal one.

MATERIALS AND METHODS
Cells, antibodies, and reagents. Drosphila S2 cells were grown and maintained as
described in Schneider's media supplemented with 10% FBS (JRH),
penicillin/streptomycin, and glutamine (9). BHK21 cells were maintained in DMEM/10%
FBS (Sigma), penicilin/streptomycin, and glutamine. Antibodies were obtained from the
following sources: anti-GFP (Invitrogen; different lots have different background bands),
anti-tubulin (Sigma), anti-VSVG (gift from R. Doms), anti-VSVM (gift from D. Lyles
and R. Hardy),and anti-phospho-Akt and anti-total Akt (Cell Signaling). Polyclonal
rabbit Anti-Atg8 was generated against peptide (FDKRRAEGDKIRRKYPDR) and
affinity purified by ProSci. Fluorescently labeled secondary antibodies were obtained
from Jackson Immunochemicals, and other secondary antibodies were obtained from
Amersham. Additional chemicals were obtained from Sigma.
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Virus and viral components. VSV-eGFP (a kind gift from J. Rose) was grown in BHK
cells as described (43). VSV was UV inactivated as described (17). Viral RNPs were
purified as described (15), and the viral RNA was purified from the RNP with Trizol
following the manufacturer's protocol. To generate VSV-G VPs, we transfected 293Ts
with pVSV-G (Invitrogen) by using Fugene HD following the manufacturer's protocol.
Supernatant was clarified, ultracentrifuged through a 20% sucrose cushion, and
resuspended in PBS.

RNAi and infections. dsRNAs for RNAi were generated and used for RNAi for 3 days
as described (8). Amplicons used are described at http://flyrnai.org. Cells were passaged
into serum-free media supplemented with dsRNA at 250 ng/20,000 cells. After 1 hr,
complete media was added. After 3 days, cells were infected with the indicated viral
inoculum and assayed at the indicated time point postinfection.

Immunofluorescence. Cells were processed for immunofluorescence as previously
described. In brief, cells were fixed in 4% formaldehyde/PBS, washed in PBS/0.1%
Triton X-100 (PBST) twice, and blocked in 2% BSA/PBST. Primary antibody was
diluted in block and incubated overnight at 4°C. Cells were washed three times in PBST
and incubated in secondary antibody for 1 hr at room temperature. Cells were
counterstained with Hoechst 33342 (Sigma) and imaged with an automated microscope
(ImageXpress Micro). Three wells per treatment and three sites per well were collected.
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Quantitation was performed with automated image analysis software (MetaXpress).
Experiments were performed at least three times.
Drosphila S2∗ cells were transfected with pMT-Gal4 and UAS-GFP-LC3 by
using Effectene (QIAGEN) per the manufacturer's protocol. After 2 days, the cells were
induced with 500 uM CuSO4, and 24 hr later, the cells were either infected or uninfected
at an MOI = 30 or transfected with Flag-RAN along with viral RNA or RNP. After 20 hr,
the cells were fixed, counterstained with Hoechst 33342, and processed for fluorescence
microscopy. More than 150 cells per treatment were counted for each experiment.
Hemocytes of the indicated genotype were obtained by dissection of third-instar
larvae in complete Schneider's media. Fifteen larvae were pooled for each of two
independent experiments. Cells were either uninfected or infected with VSV (MOI = 30),
fixed and stained with Hoechst 33342, and imaged on an inverted scope (Leica).
For Lysotracker staining of adult flies, we dissected their abdomens in complete
media, treated them with 100 nM Lysotracker Red counterstained with Hoechst 33342
for 10 min at room temp, and mounted them in complete media. The dissected fat bodies
were imaged on an inverted scope (Leica). Three animals per genotype were imaged for
each of three independent experiments.

Immunoblotting, Northern blots, and titers. Cell or flies were collected at the time
points indicated. The cells or flies were lysed in radioimmunoprecipitation assay (RIPA)
buffer supplemented with a protease inhibitor cocktail (Boehringer). Samples were
separated by 10% SDS-PAGE and blotted as previously described (9). For northern blot
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analysis, cells or flies were lysed, and total RNA was extracted with Trizol (Invitrogen)
according to the manufacturer. Ten micrograms of total RNA was run on a 1% gel and
transferred to Hybond N+ nylon, and a radiolabeled probe was generated from the
indicated gene. Experiments were performed at least three times independently. For
titering, cells were collected, freeze thawed, and titered on BHK21 cells. Flies were
crushed in DMEM/10% FBS and titered on BHK21 cells.

Electron microscopy. Cells were pretreated with the indicated dsRNA for 3 days where
indicated. Next, the cells were infected at an MOI = 5 for 20 hr and fixed in 2% PFA/2%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 hr at room temperature,
postfixed in 2% osmium tetroxide in 0.1 M sodium cacodylate, and enbloc stained with
2% aqueous uranyl acetate in maleate buffer (pH 5.2) for 30 min at room temperature.
After dehydration in a graded ethanol series, cells were removed from the dish in
propyleneoxide embedded in Epon 812. Ultrathin sections (∼70 nm) were mounted on
mesh copper grids, stained with 2% uranyl acetate in acetone followed by bismuth
subnitrite, and examined in a FEI-Tecnai T12 electron microscope; digital images were
collected with Gatan CCD camera at a primary magnification of 2100×. The number of
intracellular organelles was measured by randomly counting at least 20 cells per
treatment per experiment. At least two independent experiments were performed for each
comparison. Data were analyzed and plotted by using R (http://www.R-project.org).
Significance was assessed with a Wilcoxon test.
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Adult infections. All flies were obtained from the Bloomington stock center unless
stated otherwise and were maintained on standard medium at room temperature. Flies
carrying UAS-Atg12IR or UAS-Atg7IR (gift of T. Neufeld) or UAS-Atg18IR (VDRC)
were crossed to Actin-GAL4/+ flies at room temperature. Flies wild-type (w1118), UASPTEN, UAS-Δp60 (gift of M. Birnbaum), or UAS-Akt IR (VDRC) were crossed to heat
shock GAL4. Heat shock PTEN flies were crossed to Atg1 heterozygous flies
(Atg1[00305]). On the day of injection, the progeny were heat shocked at 37°C for 1 hour
and shocked every 2 days throughout the experiment. The 4- to 7-day-old adults of the
stated genotypes were inoculated with VSV-GFP as previously described (9). Groups of
at least 20 flies were challenged for mortality studies, and a log-rank test was used to
determine significance. Insulin (1 mg/ml) was injected in the presence or absence of
VSV-GFP. Flies were processed at the indicated time point postinfection. Flies carrying
UAS-eGFP-huLC3 were crossed to Hemolectin-Gal4 to drive expression in hemocytes
((14) and (46)).

RESULTS
VSV infection of Drosphila cells. We first characterized infection of Drosphila cells
with VSV. VSV is the prototypical member of the nonsegmented negative sense RNA
virus family and is transmitted to cattle by insects ((29) and (42)). This virus infects and
spreads between arthropods and mammals yet is controlled by the immune system of
each, resulting in little mortality in either host. To study mechanisms of defense against
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this virus, we challenged Drosphila S2 cells with VSV that expresses a GFP reporter
(VSV-GFP) upon successful replication (43).
We found that VSV-GFP replicates in Drosphila cells in a dose-dependent
manner. New viral antigens were detected by 20 hr after infection as measured by GFP
production as well as the production of the viral glycoprotein VSV-G (Figure A-1A) (8).
We also monitored viral replication with immunoblot analysis to detect the production of
viral antigens. Whole-cell lysates from cells infected with increasing multiplicities of
infection (MOI) were examined with an antibody against GFP or VSV-M (Figure A-1B).
Thus, we can monitor a dose-dependent increase in viral infection with both assays.
We also determined whether VSV productively infects Drosphila cells. To this
end, we monitored the production of new viral progeny. Cells were infected with
increasing amounts of virus, and 24 hr after infection, the amount of virus produced was
measured by plaque assay on mammalian cells, demonstrating a full replication cycle in
Drosphila cells (Figure A-1C). Thus, VSV productively infects Drosphila cells,
generating virus that is infectious to mammalian cells.

Autophagy controls viral infection in cultured cells. Drosphila has homologs of 11
yeast autophagy-related genes, and many of these have been confirmed to be required for
autophagy in flies during development or starvation (48). To test whether loss of the
autophagy pathway affects viral replication in tissue culture cells, we generated dsRNAs
against three of these highly conserved genes previously shown to be involved in
autophagy in flies (Atg5, Atg8a, and Atg18) (48). Three different genes were tested in
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order to rule out off-target effects of the dsRNAs, as well as to confirm that effects
observed are due to the autophagy pathway rather than an unrelated pathway or process
affected by any individual RNAi reagent. To deplete the proteins, we treated cells with
dsRNA for 3 days and then challenged the cells with VSV-GFP. We used automated
imaging and analysis to monitor infection. With this assay, we observed a substantial
increase in the percentage of infected cells by knocking down each autophagy-related
gene (Figure A-2A). Semiquantitative RT-PCR and RT-qPCR were used to demonstrate
that treatment with dsRNAs leads to a depletion of the cognate mRNA (Figure A-S1).
The increase in viral replication measure by fluorescence was verified biochemically;
cells were depleted for Atg5, Atg8a, or Atg18, infected with VSV, and probed by
immunoblot for GFP (Figure A-2B). We observed an increase in the amount of GFP in
the autophagy-related RNA-depleted cells.
To further validate that the autophagy pathway as a whole is required for the phenotype,
we tested additional conserved autophagy genes including Atg1, Atg2, Atg4, Atg6, Atg7,
Atg8b, or Atg9. Cells were treated with the indicated dsRNA for 3 days and then infected
with VSV. By using microscopy and automated image analyses, we quantified the
percentage of infected cells across four independent experiments and normalized the
infection to untreated cells. When compared to the nontargeting control dsRNA (β-gal),
we observed a significant increase in VSV infection upon depletion of autophagy genes
(Figure A-2C). We also found a similar increase in viral titers produced in cells depleted
for autophagy genes (Figure A-2D). Altogether, these data demonstrate that autophagy
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Figure A-1. VSV infects Drosphila cells. (A) Schneider cells were infected with VSVGFP at the indicated multiplicity of infection (MOI) for 20 hr. Cells were processed for
immunofluorescence and imaged with an automated microscope (ImagXpress Micro).
Infected cells express GFP and the viral glycoprotein VSV-G and are counterstained with
Hoechst 33342 to observe nuclei. (B) Viral antigen production at the indicated MOI at 24
hr after infection was measured by immunoblot against the virally produced antigen GFP
or the cellular control tubulin. These data show a representative experiment; similar
findings were made in at least three repetitions. (C) Viral titers from cells infected with
the indicated MOI of VSV at 24 hr postinfection. These data show a representative
experiment; similar findings were made in at least two repetitions.
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controls viral replication, consistent with its playing an antiviral role in cultured cells.

VSV infection activates autophagy in cultured cells. The finding that autophagy
inhibits VSV replication suggests that autophagy might be induced by VSV infection of
cells. Autophagy is routinely monitored by three assays: electron microscopy, fluorescent
GFP-LC3 punctae, or as lipidated LC3 by immunoblot (22). We first monitored
autophagy by electron microscopy. This approach allows identification of intracellular
organelles and structures and shows that virally induced compartments are of autophagic
origin. Double-membrane vesicles that contain cytoplasmic components or degrading
organelles such as mitochondria are not known to arise by any other mechanism.
Therefore, we performed electron microscopy analysis on both VSV-infected and
uninfected S2 cells (Figure A-3A). Higher-magnification images show double-membrane
vesicles with cytoplasmic contents or membranous contents (degrading mitochondria)
indicative of autophagic compartments (Figure A-3B). Upon quantification of autophagic
bodies, we found a > 2.5-fold increase in the number of autophagosomes in the infected
cells (Figure A-3C).
To verify that the VSV-induced vesicular structures we observed were indeed autophagic
in origin, we tested whether Atg5 depletion by RNAi could prevent their induction.
Indeed, we found that loss of Atg5 inhibited the induction of these autophagic
compartments as measured by electron microscopy (Figure A-3D). Altogether, these data
suggest that viral infection induces autophagy, which, in turn, attenuates viral replication.
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Given that VSV infection activates autophagy, there were two possible viral inducers:
incoming virions and viral replication products. To test whether virus replication is
required, we challenged cells with either replication-competent or UV-inactivated virus
and measured the effect on autophagy by using electron microscopy. UV-inactivated
virus binds cells, undergoes endocytosis, and fuses within the endolysosomal
compartment (11). The core, released into the cytoplasm, is replication incompetent. We
verified that the UV-inactivated virus was indeed replication defective by fluorescence
microscopy (Figure A-S2). By using electron microscopy, we found that both replicationcompetent and UV-inactivated VSV induce autophagic vesicles (Figure A-3C). Indeed,
quantification reveals that UV-inactivated virus induces the formation of autophagic
bodies to a similar extent as replication-competent virus. This suggests that the incoming
virus presents the cells with a pre-existing molecule (perhaps a pathogen-associated
molecular pattern [PAMP]) that is sufficient to activate the antiviral program.
During autophagy, cytosolic LC3 (LC3-I) is conjugated on its carboxyl terminus
with phosphatidylethanolamine, forming lipidated LC3 (LC3-II), which localizes to the
autophagic membrane. The amount of LC3-II correlates with the number of
autophagosomes and can be monitored by immunoblot (22). In Drosphila, there are two
LC3 homologs that are 95% similar, Atg8a and Atg8b. We developed an antibody that
recognized the C terminus of both homologs because treatment of cells with dsRNA
against Atg8 (dsRNA has overlap with both targets) completely abolished the signal
(Figure A-3E). In addition, we observed an increase in the production of Atg8-II

128	
  
	
  
	
  
	
  

Figure A-2. Autophagy is antiviral in Drosphila cells. (A) S2 cells were pretreated with
dsRNA against control dsRNA (luciferase) or the autophagy genes Atg5, Atg8a, or Atg18
for 3 days and then infected (MOI = 1) for 20 hr and processed for immunofluoresence
and imaged as above. Infected cells express GFP, and the percent infection is calculated
with automated image analysis (MetaXpress) from three wells, with three sites per well.
Loss of autophagy genes significantly increases VSV infection (p < 0.05). (B) Depletion
of autophagy genes increases the production of viral antigens by immunoblot. Cells
pretreated with the indicated dsRNAs were infected (MOI = 0.1) and processed for
immunoblot at 24 hr after infection. Viral antigens were measured by anti-GFP and
normalized to the control protein tubulin. These data show representative experiments;
similar findings were made in at least three repetitions. (C) Depletion of additional
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autophagy genes by RNAi leads to an increase in the percent infection as compared to
control dsRNA. Mean ± SD are shown for four independent experiments as the fold
effect compared to control dsRNA (MOI = 0.1–0.25, 24 hr postinfection); ∗p < 0.05,
Student's t test. (D) Viral titers of cells pretreated with the indicated dsRNAs at 48 hr
postinfection with an MOI = 0.1. Data are presented as the mean ± SD fold change from
control treatment of four averaged experiments; ∗p < 0.01, Student's t test.
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upon starvation, validating our antibody (Figure A-3F). Next, we tested whether infection
with wild-type or UV-inactivated virus induced the production of Atg8-II. Indeed, we
observed marked induction of Atg8-II upon treatment with both replication-competent
and replication-incompetent virus (Figure A-3F).

VSV induces autophagy as measured by GFP-LC3 punctae formation. To further
study the role of autophagy in VSV infection, we took advantage of an assay that depends
on the translocation of the autophagosome protein LC3 (Atg8) from the cytosol (diffuse
distribution) to newly formed autophagosomes, which appear as bright cytoplasmic
punctae (20). GFP-LC3 is an autophagosome-specific membrane marker detected in
punctae upon autophagosomes induction in both mammalian and Drosphila systems (
(46), (48) and (57)). This assay allows us to monitor the induction of autophagy cell by
cell. We expressed this GFP-tagged LC3 (GFP-LC3) in cultured cells and found that
there is diffuse cytoplasmic staining (Figure A-4A). However, upon infection with either
wild-type or UV-inactivated virus, we observed a significant increase in the percentage of
punctae-containing cells (Figure A-4B). Moreover, we found that there was also an
increase in the number of punctae per cell upon infection with either wild-type or UVinactivated VSV (Figure A-4C). Lastly, we tested whether the activation of autophagy
was cell autonomous. To this end, cells expressing GFP-LC3 were uninfected, infected,
or infected at a multiplicity of infection such that 30% of the cells were VSV-M+. Next,
we quantified the percentage of cells with punctae that were either VSV+ or VSV−. We
found that only the infected cells had an increase in GFP-LC3 punctae (Figure A-4D).
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Together, the combination of electron microscopy, the induction of Atg8-II, and GFPLC3 punctae formation shows that VSV infection, in the absence of viral replication, led
to a robust, cell-autonomous increase in autophagy in Drosphila cells.

The viral glycoprotein, VSV-G, induces autophagy. The VSV virion is largely
composed of: the viral RNA genome; the proteins that are bound to the viral RNA that
makes up the RNA-nucleoprotein complex (RNP); matrix proteins associated with the
nucleocapsid; and the membrane-bound surface envelope spike glycoprotein that extends
from the viral membrane. We set out to determine which component of the virion is the
PAMP that is recognized by Drosphila cells, leading to the induction of antiviral
autophagy. To this end, we purified virions from which we isolated the RNP and the viral
RNA (15). Because VSV is a negative-strand RNA virus, the naked nucleic acid is not
capable of initiating an infection in the absence of the viral proteins that make up the
RNP (VSV proteins: N, P, and L). We verified that the purified RNA was nonfunctional
and that the RNP was functional by cotransfection with a reporter to mark the transfected
cells (Figure A-S3A). We tested whether cells transfected with the viral RNA or RNP
induced autophagy as measured by GFP-LC3 punctae formation and found that neither
PAMP induced autophagy with this assay (Figures A-4E and A-4F).
Next, we set out to test whether the viral glycoprotein VSV-G could induce
autophagy. To purify VSV-G-containing vesicular particles (VPs) devoid of any other
viral component, we either mock transfected or transfected 293T cells with VSV-G.
VSV-G alone is sufficient to induce blebbing and the formation of VPs that are
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Figure A-3. VSV infection activates autophagy independent of replication. (A) VSV
infection induces autophagosome formation as measured by electron microscopy.
Representative images are shown for cells that are either uninfected or infected at an MOI
= 5 at 20 hr after infection. (B) Higher-magnification images of autophagosomes in VSVinfected cells. (C) Active and UV-inactivated virus induce autophagic vesicles. Cells
were infected with UV-inactivated VSV-GFP as above. Autophagic bodies were counted
for at least 20 cells from each treatment and presented as a notched box plot. The
horizontal dark line represents the median for each category. The box represents the
interquartile range, and the whiskers encompass the most extreme data values. The
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notches represent a confidence interval for the median, and nonoverlapping notches
indicate different medians at the 5% significance level. There is a significant difference
between uninfected and infected or UV-virus infected (∗p = 9.0e−5 and p = 3.7e−3,
Wilcoxon test), respectively. However, there is no significant difference in the number of
autophagosomes per cell between infected and UV-virus infected (p = 0.22, Wilcoxon
test). (D) The induction of autophagic vesicles by VSV is Atg5 dependent. S2 cells were
pretreated with either control (LacZ) or Atg5 dsRNA for 3 days and infected with VSVGFP at an MOI = 5 for 20 hr. Autophagic bodies were counted for 35 cells from each
treatment and presented as a notched box plot as described in (C). There is a significant
difference between control and Atg5-depleted cells (∗p = 1.2e−07, Wilcoxon test). These
findings were observed in at least two independent experiments. (E) Immunoblot analysis
of cells treated with control dsRNA or dsRNA against Atg8 (Atg8a and Atg8b). Atg8 is
observed in resting cells (Atg8-I, ∼16 kD). (F) A smaller form of Atg8 is induced in cells
that are serum starved or cells that are infected with VSV or UV-inactivated VSV (Atg8II, ∼14 kD). These data show representative experiments; similar findings were made in
at least three repetitions.
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infectious and have no other viral component ((1) and (45)). We purified the VPs and
found that only the VPs from the VSV-G-transfected cells carry VSV-G by immunoblot
(data not shown) and that Drosphila cells treated with the VSV-G VPs, but not the
preparation from mock-transfected cells, were positive for VSV-G by
immunofluorescence (Figure A-S3B). Next, we challenged cells expressing GFP-LC3
with the purified blebs and found that treatment of cells with VSV-G+ VPs was sufficient
to induce LC3-GFP+ punctae (Figure A-4G). Taken together, our data suggest that VSVG is the PAMP that is recognized by Drosphila cells.

VSV infection induces autophagy both in primary cells and in adult flies. We
extended our findings to primary cells by taking advantage of transgenic animals that
express GFP-LC3 in larval hemocytes. Hemocytes are the Drosphila phagocytic
macrophage-like cell type from which S2 cells are derived. We used the Gal4-UAS
system, in which transgenes under the control of Gal4 transcription factor-binding sites
(UAS sites) can be induced by Gal4 expression (5). This allows us to drive expression of
the autophagosome marker GFP-LC3 with a specific hemocyte promoter, hemolectin.
Third-instar larval hemocytes expressing GFP-LC3 (hemolectin-Gal4, UAS-GFP-LC3)
were isolated and challenged with VSV ex vivo. In uninfected primary hemocytes, there
is diffuse, low GFP-LC3 expression (Figure A-5A). In contrast, by 2 hr after infection,
the hemocytes show bright GFP-positive punctae indicative of autophagosome induction
(Figures A-5A and A-5B). This time point is prior to the initiation of viral replication,
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further supporting the hypothesis that a preformed component of the virus, rather than
replicating virus, is recognized by cells to induce autophagy.
To further demonstrate that infection induces autophagy in vivo, we infected adult
flies with VSV-GFP and monitored autophagy with Lysotracker staining, a marker for
acidified compartments that has been extensively used in flies ((4), (7) and (19)). With
this assay, we found that VSV infection (GFP expression) leads to an increase in
autophagy (Lysotracker+) in vivo (Figure A-5C). Moreover, this induction is again cell
autonomous; only GFP+ cells were Lysotracker+. These data show that both Drosphila
cells and animals respond to VSV infection by inducing an autophagic program.

Autophagy plays an antiviral role in adult flies. To determine whether autophagy also
plays an innate antiviral role in the adult organism in vivo, we characterized viral
infection of adult flies by challenging them with VSV and monitored infection. We found
that VSV infection is nonpathogenic in adult flies as measured by mortality postinfection
(Figure A-6A). We next set out to determine whether depletion of autophagy genes alters
the susceptibility of flies to infection. Mutant flies were generated in vivo by driving
expression of transgenes bearing long hairpin double-stranded RNA constructs targeting
specific autophagy genes in vivo, leading to loss-of-function phenotypes. We crossed
control and transgenic flies with hairpin transgenes against Atg18 (UAS-Atg18 IR),
previously shown to be required for starvation-induced autophagy in flies, to actinGAL4, resulting in high levels of ubiquitous transgene expression (48). We validated that
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Figure A-4. VSV infection induces autophagy in Drosphila cells. VSV induces
autophagosomes as measured by LC3 relocalization. (A) Drosphila cells were transfected
with a GFP-LC3 reporter (green). Cells were either uninfected or infected with wild-type
VSV or UV-inactivated VSV for 24 hr, fixed, and probed with anti-VSVM (red) and
Hoechst 33342 (blue). A representative image is shown. Arrows indicate GFP-LC3+
punctae. (B) The percentage of cells with punctae was counted for five experiments, and
fold change was graphed for cells that were uninfected (blue) or cells that were infected
with wild-type VSV (red) or UV-inactivated VSV (green). Error bars represent SD. ∗p <
0.01, Student's t test. (C) The number of punctae per cell normalized to 100% for each
treatment (n > 150 for each condition) quantified postinfection with either VSV or UVinactivated VSV. (D) The induction of GFP-LC3 punctae is cell autonomous. The
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percentage of cells with punctae was counted for three experiments, and fold change was
graphed for cells that were either uninfected (blue), infected (red), or uninfected in a well
in which 30% of the cells were infected (orange). Error bars represent SD. ∗p < 0.01,
Student's t test. (E) The percentage of punctae+ cells transfected with control (red) or
viral RNA (blue) was counted for three experiments, and fold change was graphed. Error
bars represent SD. (F) The percentage of punctae+ cells transfected with control (red) or
viral RNP (blue) was counted for three experiments, and fold change was graphed. Error
bars represent SD. (G) The percentage of punctae+ cells infected with control (red) or
VSV-G+ VPs (blue) was counted for three experiments, and fold change was graphed.
Error bars represent SD. ∗p < 0.01, Student's t test.
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Atg18 is indeed depleted in these flies by semiquantitative RT-PCR and RT-qPCR
(Figure A-S1). Whereas UAS-Atg18 IR singly transgenic flies and flies expressing a
control dsRNA (Figure A-S4) were resistant to VSV-induced lethality, actinGAL4>UAS-Atg18 IR doubly transgenic flies that were depleted for Atg18 became
sensitive to infection and succumbed to the virus (Figure A-6A). Flies depleted for Atg18
had a normal life span and were not more sensitive to infection with Drosphila C virus
(Figure A-S4). Together, this shows that the altered pathology of the autophagy mutant is
specific and that this pathway is protective against VSV infection.
We also found that the increased mortality correlates with increased viral
replication in flies. At all time points after infection, there was a marked increase in the
amounts of VSV antigen production, as measured by immunoblot (Figure A-6B), and
increased virus production by plaque assay (Figure A-6C). Taken together, our data
suggest that loss of autophagy in adult flies leads to increased viral replication, leading to
mortality from an otherwise nonlethal infection.
To verify that our data for Atg18 is due to an effect on autophagy and not another
role for Atg18, we tested whether depletion of additional autophagy genes Atg7 or
Atg12, which were previously shown to be required for starvation-induced autophagy in
flies, also affects viral replication (48). We found that there was a significant increase in
the amount of VSV RNA replication in animals depleted for Atg18 (Figure A-6D), Atg7
(Figure A-6E), or Atg12 (Figure A-6F) as measured by RNA blot. We also monitored
viral replication by immunoblot analysis of the virus-encoded GFP and again
139	
  
	
  
	
  
	
  

Figure A-5. VSV infection induces autophagy in primary cells and in adult flies. (A)
Primary hemocytes expressing GFP-LC3 (Hml-gal4>UAS-eGFP-huLC3, green) were
either uninfected or infected ex vivo for 2 hr and then fixed and stained with Hoechst
33342 to visualize nuclei (blue) by fluorescence microscopy. A representative image is
shown. (B) The percentage of cells with punctae was counted (n > 40 for each condition).
Error bars represent the range of two independent experiments. Increased punctae
formation is observed in the infected cells. ∗p < 0.001, chi-square test in each
experiment. (C) Adult wild-type flies were infected with VSV-GFP for 3 days. The flies
were monitored for infection (GFP+) and autophagy (Lysotracker+) and were
counterstained with Hoechst 33342 to observe the nuclei. There is increased Lysotracker
staining in the infected cells in vivo in the animal. White arrows indicate that cells that
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are Lysotracker+ are also GFP+. Blue arrows (merged image) show that the GFP− cells
throughout the tissue are not Lysotracker+. These data show representative experiments;
similar findings were made in at least three repetitions.
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observed a significant increase in viral growth in flies depleted for the autophagy genes
Atg7 and Atg12 (Figure A-S5). We also validated that RNAi itself does not impact viral
replication by expressing a control dsRNA against the β-galactosidase gene and found
that there was no effect on viral growth (data not shown). Next, we determined whether
loss of Atg7 also had an effect on survival postchallenge with VSV. Indeed, we found
that, whereas UAS-Atg7 IR singly transgenic flies were resistant to VSV-induced
lethality, actin- GAL4>UAS-Atg7 IR doubly transgenic flies were more sensitive to
infection, although it takes longer to succumb to the infection (Figure A-S4).
Lastly, we tested whether loss of Atg18 had an effect on hemocyte numbers or
functionality. To monitor this phagocytic cell type, we injected flies that were either
wild-type or depleted for Atg18 with fluorescent beads that are efficiently phagocytosed
by hemocytes, allowing for the number and activity of this cell type to be monitored (12).
We found that there was no difference in the number of hemocytes or the level of
phagocytic activity in the hemocytes of adult flies depleted for Atg18 (Figure A-S6).
Taken together, we demonstrate that autophagy is induced by infection, inhibits VSV
replication, and prevents viral pathogenesis in animals.

Nutrient signaling controls autophagy during viral infection in animals. Given that
autophagy is induced by infection, we were interested in determining which signaling
pathway might control this antiviral response. The PI3K-Akt pathway has been
previously shown to regulate autophagy during development and starvation. Therefore,
we tested whether this pathway also senses VSV infection in vivo. In resting cells,
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Figure A-6. Autophagy is antiviral in adult flies. (A) Adult flies expressing ubiquitous
and high amounts of dsRNA against Atg18 (Actin-Gal4>UAS-Atg18IR) or sibling
controls (+>UAS-Atg18IR) were challenged with 104 plaque-forming units (pfu) VSV,
and morbidity was monitored as a function of time after infection. Log-rank test reveals
that loss of Atg18 significantly increases susceptibility (p < 0.001). A representative
experiment is shown; similar findings were made in at least three experiments. (B) Adult
flies expressing ubiquitous and high amounts of dsRNA against Atg18 (ActinGal4>UAS-Atg18IR) or their sibling controls (+>UAS-Atg18IR) were challenged with
VSV and monitored over time for viral replication, as measured by immunoblot against
virally produced GFP, and normalized to a cellular control protein. Asterisk indicates a
nonspecific band. (C) Adult flies expressing ubiquitous and high amounts of dsRNA
against Atg18 (Actin-Gal4>UAS-Atg18IR, black bars) or their sibling controls (+>UAS143	
  
	
  
	
  
	
  

Atg18IR, white bars) were challenged with VSV and monitored over time for viral
replication as measured by viral titers. (D) Adult flies expressing ubiquitous and high
amounts of dsRNA against Atg18 (Actin-Gal4>UAS-Atg18IR) or their sibling controls
(+>UAS-Atg18IR) were challenged with VSV and monitored over time for viral
replication as measured by RNA blot. (E) Adult flies expressing ubiquitous and high
amounts of dsRNA against Atg7 (Actin-Gal4>UAS-Atg7IR) or their respective sibling
controls (+>UAS-Atg7IR) were challenged with VSV and monitored over time for viral
replication as measured by RNA blot. (F) Adult flies expressing ubiquitous and high
amounts of dsRNA against Atg12 (Actin-Gal4>UAS-Atg12IR) or their respective sibling
controls (+>UAS-Atg12IR) were challenged with VSV and monitored over time for viral
replication as measured by RNA blot.
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autophagy is repressed, at least in part, by the PI3K-signaling pathway. Akt, a key kinase
in this pathway, has been demonstrated to control autophagy via activation of the TOR
kinase (35). TOR is a global cell regulator that responds to nutritional conditions and
represses autophagy via Atg1 ((27) and (47)). Inhibiting this pathway either by decreased
inputs from extracellular ligands or by overexpression of negative regulators leads to
decreased signaling and increased autophagy ((46) and (48)).
To modulate this pathway and test whether the PI3K-Akt pathway controls VSVinduced autophagy, we took advantage of a well-studied negative regulator, PTEN.
PTEN is a phosphatase that blocks PI3K signaling by dephosphorylating PI(3,4,5)P3
(55). Overexpression of this factor leads to an increase in autophagy in the larval fat body
((3) and (48)). We overexpressed this gene in transgenic animals with a heat shock Gal4
driver and found that there was no effect on fly viability (data not shown). We tested
whether PTEN also controls autophagy in the adult fat body by using Lysotracker, a
standard assay in Drosphila ((4), (7) and (19)). With this assay, we found that
overexpression of PTEN induces autophagy in fat bodies of well-fed adults (Figure AS7).
We then challenged flies overexpressing PTEN and thus undergoing constitutive
autophagy with VSV and monitored viral replication. We observed a decrease in viral
protein production compared to controls by immunoblot analysis (Figure A-7A). To
further dissect the role of PI3K signaling in the control of VSV infection, we tested
whether inhibition of the pathway with a different negative regulator also blocks
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infection. We took advantage of a deleted form of p60, the adaptor that couples the
insulin receptor to the catalytic subunit of PI3K, Dp110 (6). This deletion mutant, Δp60,
is a variant that lacks the Dp110-binding domain, which, when overexpressed, inhibits
the PI3K-Akt-signaling pathway similarly to the overexpressed PTEN, thereby leading to
an increase in autophagy (48). By using the same heat shock GAL4 overexpression
system to drive expression of Δp60, we also observed a decrease in VSV replication as
measured by immunoblot (Figure A-7A). Together, these data indicate that inhibition of
the PI3K-Akt pathway, which, in turn, activates autophagy, also inhibits VSV replication,
suggesting that this pathway plays an important role in the antiviral response.
To verify that the increase in VSV replication observed upon inhibition of the
PI3K-Akt pathway is indeed due to activation of autophagy and not another pathway
regulated by this signaling cascade, we performed epistasis analysis. Atg1, a conserved
serine-threonine-specific protein kinase, is a crucial component of the autophagy
machinery and a key regulator of autophagy. Loss of Atg1 blocks autophagy, whereas
overexpression leads to an increase in autophagy in flies ((48) and (47)). Therefore, it is a
limiting component of this pathway. First, we tested whether loss of one copy of Atg1
had an effect on infection and found that this had no effect on VSV levels (Figure A-S8).
Next, we performed the epistasis analysis in a sensitized background by crossing flies
carrying a heat shock promoter driving expression of PTEN (heat shock PTEN) to flies
that were heterozygous for Atg1. This allowed us to compare flies that overexpressed
PTEN and had two copies of Atg1 to flies that were heterozygous for Atg1. We expected
that the decreased viral replication mediated by overexpression of PTEN would be
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attenuated in animals that had reduced Atg1 levels. We challenged these siblings and
found that removing one copy of Atg1 relieves the PTEN-mediated repression of VSV
replication (Figure A-7B). This experiment demonstrates that the effect of PTEN on VSV
is mediated by an increase in autophagy.
The previous experiments relied on overexpression phenotypes; therefore, we
tested whether we observed a similar dependence on nutrient signaling by using a loss-offunction strategy. Loss of Akt signaling is predicted to activate autophagy and inhibit
VSV replication. To this end, we tested whether loss of Akt by RNAi, by using a
previously validated transgene, would result in decreased viral replication (54). We found
that depletion of Akt by RNAi led to a decrease in VSV replication as measured by
immunoblot (Figure A-7C).
Together, these data suggest that infection by VSV is sensed by flies, leading to a
decrease in PI3K/Akt signaling, which increases autophagy and inhibits viral replication.
However, these data do not show whether infection itself modulates this signaling
pathway. A prediction is that VSV infection is sensed by the fly, leading to the repression
of PI3K/Akt signaling to activate the antiviral autophagy program. We set out to test this
hypothesis by monitoring signaling during infection. One method to monitor signaling
through this pathway is to measure the levels of phosphorylation of Akt by immunoblot.
We challenged the flies with VSV and compared the amounts of phospho-Akt to flies that
were uninfected. We observed a substantial decrease in amounts of phospho-Akt in VSVinfected animals (Figure A-7D). In contrast, total Akt protein remained constant. Thus,
VSV infection leads to an inhibition of Akt signaling in animals.
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DISCUSSION
Although autophagy has been implicated in diverse processes, both normal and
pathogenic, a role in controlling viral replication has been difficult to demonstrate
directly in vivo and is complicated by differing requirements by distinct pathogens. With
a new model system, we found that autophagy plays an important antiviral role against
VSV in tissue culture cells as well as in adult flies. By modulating the pathway in vivo—
either inhibiting it with RNAi against components of the autophagic machinery or
activating it by repressing the function of upstream members of the PI3K/Akt-signaling
pathway—we demonstrate a reciprocal effect on viral replication: activation of autophagy
inhibits, and inhibition of autophagy exacerbates infection. Moreover, we showed that
infection is sensed by flies and leads to inhibition of the Akt-signaling pathway. This, in
turn, leads to activation of the antiviral autophagic program, thereby protecting the
animal from an otherwise lethal virus infection.
Furthermore, our data suggest that autophagy is directly activated by VSV
infection, most likely via the surface glycoprotein VSV-G, and thus activation does not
require viral replication. Although VSV RNA can be recognized by the cytoplasmic
sensors in mammals, we showed that VSV RNA was not the sensor for autophagy in
flies. Moreover, this class of intracellular sensors has not yet been identified in
Drosphila. Interestingly, recent work in mammalian systems indicates that VSV-G can
also be recognized by TLR4 to activate this class of pattern recognition receptors (PRRs)
(13). It has been observed that TLR4 signaling can activate autophagy downstream of
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Figure A-7. The PI3K-Akt pathway controls autophagy and viral replication in
adult flies. (A) Flies carrying a heat shock-inducible Gal4 were crossed to UAS-PTEN,
UAS-Δp60, or control at room temperature. Progeny were collected and heat shocked at
37°C for 1 hr on the day of infection and every 2 days after challenge. Viral replication
was monitored over time for viral replication by immunoblot against virally produced
GFP and normalized to cellular proteins. (B) Flies carrying a heat shock-inducible PTEN
were crossed to flies heterozygous for a mutant Atg1 allele at room temperature. Progeny
were collected and heat shocked at 37°C for 1 hr on the day of infection and every 2 days
after challenge. Viral replication was monitored over time for viral replication by
immunoblot against virally produced GFP and normalized to a cellular control protein.
(C) Flies carrying a heat shock-inducible Gal4 were crossed to UAS-Akt IR at room
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temperature. Progeny were collected and heat shocked at 37°C for 1 hr on the day of
infection and every 2 days after challenge. Viral replication was monitored over time for
viral replication by immunoblot against virally produced GFP and normalized to cellular
proteins. (D) Flies were injected with insulin in the presence or absence of VSV.
Phospho-Akt and Total-Akt were monitored by immunoblot. These data show
representative experiments; similar findings were made in at least three repetitions.
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the bacterial PAMP LPS, suggesting a link between pattern recognition by TLRs and the
cellular antimicrobial response (56). Drosphila has nine TLRs, raising the possibility that
this VSV-G-dependent viral recognition pathway uses this class of pattern recognition
receptors; however, other receptors may be involved. Previous studies found that, in
specialized antigen-presenting dendritic cells that are not competent for VSV replication,
autophagy is required to present VSV antigens to endosomal TLR7, suggesting that
different aspects of the autophagic pathway may modulate viral replication under
different conditions or in specialized cell types (26).
Autophagy has been shown to be essential for defense against a variety of
pathogens in cell culture. Our studies suggest that VSV-G is recognized by a pattern
recognition receptor whose activation leads to inhibition of the PI3K-signaling pathway,
increasing autophagy and thereby blocking viral replication. Importantly, this newly
identified antiviral pathway may play a role in the control of additional infectious agents.
Moreover, it may be fruitful to explore pharmacological modulation of the pathway as a
means to inhibit viral replication because there are a number of small molecule
modulators that have been developed to regulate the PI3K-Akt-signaling pathway.
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SUPPLEMENTAL DATA

Figure A-S1. dsRNA against autophagy genes is efficacious both in cells and flies as
measured either by semiquantitative RT-PCR or RT-qPCR. (A) >75% depletion of
the cognate message as measured by semi-quantitative RT-PCR against Atg18 (orange)
or Atg8a (green) normalized to a cellular control (clathrin heavy chain). Control dsRNA
treated samples are set to 100%. (B) Semi-quantitative RT-PCR against Atg18
normalized to control (clathrin heavy chain). Adult flies expressing ubiquitous and high
level dsRNA against Atg18 (Actin-Gal4; UAS-Atg18IR) were compared to sibling
controls (+; UAS-Atg18IR) which were set to 100%. C. RT-qPCR against Atg18
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normalized to control (rp49) in adult flies as in B. or in cells pre-treated with the
indicated dsRNAs.
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Figure A-S2. Schneider Cells Were Infected with VSV-GFP (MOI=9) or UVInactivated VSV-GFP (Equivalent Volume) for 20 Hours. Cells were processed for
immunofluorescence and imaged using an automated microscope (ImagXpress Micro).
There were no Gfp+ cells in the UV inactivated sample.
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Figure A-S3. Purified viral components reveal that VSV G is the PAMP. (A) Purified
VSV RNP but not VSV RNA is infectious when transfected into cells. Schneider cells
were co-transfected with Flag-tagged RAN and either VSV RNA (left) or VSV RNP
(right). Cells were processed for immunofluorescence with anti-FLAG (red), anti-VSV M
(green) and nuclei (blue) and imaged. There were no VSV-M+ cells in the viral RNA
transfected sample while >95% of the Flag+ (transfected) cells were VSV-M+. (B) Cells
treated with VPs from VSV G transfected 293s but not blebs from mock-transfected cells
are VSV G+ and induce GFP-LC3 punctae. Cells were transfected with GFP-LC3 and
then treated with VPs and processed for fluorescence with GFP-LC3 (green), anti-VSV G
(red) and nuclei (blue).
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Figure A-S4. Depletion of autophagy in adult flies specifically impairs VSV
susceptibility. Flies of the indicated genotypes were challenged with (A) PBS or (B)
Drosphila C Virus (DCV) or (C) VSV. (D) VSV and monitored daily for mortality. Log
rank test reveals that loss of Atg7 significantly increases susceptibility (p<0.05). A
representative experiment is shown. Each challenge was repeated at least three times.
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Figure A-S5. Autophagy controls VSV but not DCV infection in adult flies.
Adult flies expressing ubiquitous and high-level dsRNA against either Atg12 (ActinGal4; UASAtg12IR) or Atg7 (Actin-Gal4; UAS-Atg7IR) or their respective sibling
controls (+; UASAtg12IR or +; UAS-Atg7IR) were challenged with VSV and monitored
over time for viral replication as measured by immunoblot against virally produced GFP
and normalized to a cellular control protein. There is a significant increase in VSV
replication in flies depleted for autophagy genes measured by protein production. *
indicates nonspecific background band.
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Figure A-S6. Atg18-depleted flies have wild-type numbers of hemocytes that are
functional as measured by phagocytic activity. Adult flies were injected with 0.2um
red fluorescent beads. Three days later the flies were processed for fluorescence
microscopy. Hemocytes are the only phagocytic cells which take up fluorescent beads,
which can be readily visualized through the cuticle and are distributed throughout the
abdomen. Top panels at low magnification and the indicated inset is shown at higher
magnification to show individual cells that have taken up multiple beads. Areas of
increased saturation in top panels are likely aggregated hemocytes.
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Figure A-S7. Flies carrying a heat shock-inducible Gal4 were crossed to UAS-PTEN
or control at room temperature. Progeny were collected and heat shocked at 37C for
one hour the day before and the day of staining. Autophagy was monitored using
Lysotracker staining to visualize the autophagosomes and counterstained with Hoescht
33342 to observe the nuclei. There are increased acidic compartments in the fat body
cells of well-fed flies expressing the negative regulator PTEN compared to the diffuse
dim staining in the control fat body cells.
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Figure A-S8. Heterozygous ATG1 mutants carry wild-type levels of VSV. Flies of the
indicated genotypes were challenged with VSV and monitored by immunoblot at the
indicated time post infection.
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